

CURRICULUM VITAE ET STUDIORUM

VINCENZO BRONTE, M.D.

e-mail: vincenzo.bronte@univr.it

PRINCIPALI RISULTATI SCIENTIFICI

Il prof. Vincenzo Bronte, M.D., ha iniziato la sua carriera presso l'Università degli Studi di Padova e ha proseguito la sua attività di ricerca presso il laboratorio diretto dal prof. Restifo al Surgery Branch del National Cancer Institute (NIH, Bethesda, MD, USA). Durante tale periodo è stato direttamente coinvolto in ricerche riguardanti l'Immunologia e l'Immunoterapia del cancro, diventando uno dei massimi esperti mondiali nello sviluppo di nuovi approcci immunoterapeutici per la cura del cancro.

In questi anni, il prof. Bronte è stato tra i pionieri nell'identificazione e caratterizzazione delle cellule mieloidi con funzione immunoregolatoria, chiamate "cellule mieloidi soppressorie", (MDSC), la cui attività riduce l'efficacia di nuovi farmaci con attività antitumorale.

Dopo l'esperienza all'estero, è ritornato in Italia presso l'Università-Azienda Ospedaliera di Padova, per poi successivamente spostarsi presso l'Università-Azienda Ospedaliera Universitaria Integrata (AOUI) di Verona, dove ha proseguito i suoi studi di immunologia del cancro.

Durante la sua carriera, il prof. Bronte ha contribuito alla caratterizzazione degli aspetti molecolari ed enzimatici in grado di controllare l'attività immunosoppressoria delle cellule MDSC definendo, per la prima volta, il ruolo degli enzimi arginasi e ossido nitrico sintasi, coinvolti nel metabolismo dell'aminoacido arginina e nella regolazione della immunosoppressione mediata dalle cellule MDSC. Ha inoltre contribuito agli studi volti a definire le MDSC a livello clinico sia come potenziali indicatori dello stadio tumorale e fattori in grado di predire la risposta alle terapie che come bersagli molecolari per alterare i loro effetti negativi nei soggetti affetti da tumore, un concetto ora testato in molti protocolli clinici. I risultati pubblicati dal prof. Bronte hanno chiaramente dimostrato che la funzione degli enzimi arginasi e ossido nitrico sintasi diminuisce l'attività antitumorale dei linfociti T, ma che tuttavia è possibile modificare i tumori definiti "cold" ovvero con pochi infiltrati linfocitari,

indice di bassa immunogenicità, usando composti chimici di piccole dimensioni in grado di inibire questi enzimi e, di conseguenza, ristabilire l'infiltrato delle cellule T all'interno della massa tumorale e la loro attività.

Inoltre, il prof. Bronte ha anche contribuito attivamente allo sviluppo dell'immunoterapia anti-tumorale sfruttando sia strategie immunoterapeutiche basate su vaccini a DNA, adiuvanti di nuova generazione a nanoparticelle con proprietà immunomodulatorie, che approcci di immunoterapia passiva basati sul trasferimento adottivo di linfociti T.

Il prof. Bronte è autore di circa 193 articoli pubblicati in riviste scientifiche internazionali peer-reviewed, 17 monografie di ricerca in capitoli di libri. Nel 2008, la prestigiosa rivista "Science" ha dedicato un articolo al prof. Bronte ed al collega americano Dmitry Gaborovich come autori di una delle più importanti scoperte scientifiche nel campo dell'immunologia dei tumori: l'identificazione delle cellule MDSC (Marx J. Cancer Immunology. Cancer's bulwark against immune attack: MDS cells. Science. 2008, 319:154-6). Il suo H-index è di 71 sul database "Scopus" (con 23652 citazioni), di 67 sul database "Web of Science" (con 21985 citazioni) e di 77 (i10-index di 154) su "Google Scholar" (con 32419 citazioni). Tra i suoi articoli di ricerca, 23 hanno ricevuto almeno un approfondimento e 13 di questi articoli sono stati valutati dai professori presenti in "Faculty of 1000".

Il prof. Bronte è inoltre inventore di 9 brevetti. Negli ultimi 10 anni, il prof. Bronte ha partecipato come relatore a più di 190 congressi nazionali e internazionali. È stato incluso nella lista dei più citati ricercatori (Highly Cited Researchers) del 2018, 2019 e 2020 da parte del "Clarivate Analytics" (per un totale di 147 scienziati nel campo dell'Immunologia). Questo elenco riconosce i ricercatori di livello mondiale selezionati per le loro eccezionali prestazioni di ricerca, dimostrate dalla produzione di numerosi articoli con più alto numero di citazioni per settore e anno in *Web of Science* ([Highly Cited Researches](#)).

EDUCAZIONE

- 07/18/1988: Laurea in Medicina e Chirurgia summa Cum Laude, Università degli Studi di Padova, Italia.
- 12/21/1992: Specializzazione (70/70) in Allergia e Immunologia, Università degli Studi di Padova, Italia.

ESPERIENZA PROFESSIONALE

- Febbraio 1994 - Settembre 1996: esperienza come “exchange scientist” al Surgery Branch del National Cancer Institute, National Institute of Health, Bethesda, MD, USA.
- 1990 - 1992: Borsa Post-dottorato finanziata dall’Associazione Italiana per la Ricerca sul Cancro (AIRC).
- 1988 - 1989: Borsa di studio finanziata da Fidia Pharmaceuticals – progetto di ricerca sviluppato presso l’istituto di Oncologia dell’Università degli Studi di Padova, Italia.
- Novembre - Dicembre, 1989: visiting fellow presso i laboratori Roche, Basilea, Svizzera.

PREMI E ONORIFICENZE

- Gennaio 2019: Vincitore del premio “*Veronese dell’anno 2018*” per i risultati raggiunti nel campo dell’immunoterapia del cancro, conferito dal Comune di Verona, Italia.
- Novembre 2008: Vincitore del Premio “*Guido Venosta*” per ricercatori in oncologia, conferito dalla Fondazione Italiana per la Ricerca sul Cancro (FIRC).
- Luglio 2008: Vincitore del Premio “*Timone d’argento*”, per siciliani che si sono distinti nel campo dell’arte, letteratura, economia, sport e scienza, conferito dal Lion’s Club di Gela, Italia.
- Aprile 2007: Vincitore del Premio Internazionale “*Francesco De Luca*” per la carriera scientifica in Oncologia, conferito dall’Accademia Nazionale dei Lincei, Roma, Italia.

POSIZIONE

- Da Gennaio 2011 ad oggi: Professore Ordinario di Immunologia e Direttore della Sezione di Immunologia afferente al Dipartimento di Patologia e Diagnostica fino al 2015, e dal 2015 ad oggi al Dipartimento di Medicina dell’Università degli Studi di Verona, Italia; Direttore dell’Unità Operativa di Immunologia dell’Azienda Ospedaliera Universitaria Integrata di Verona (AOUI), Italia;
- Dicembre 2018 - Dicembre 2020: Direttore della scuola di dottorato “Scienze della vita e della salute” presso l’Università degli Studi di Verona, Italia.

- 2007-2014: Capo gruppo presso l'Istituto Veneto di Medicina Molecolare (VIMM), Padova, Italia.
- 1997-2010: Direttore del Laboratorio di tipizzazione HLA e dell'Unità di Oncogenomica presso l'Istituto Oncologico Veneto di Padova, Italia.
- 1992-2010: Dirigente Medico presso l'Istituto Oncologico Veneto (IRCCS) Padova, Italia; Professore a contratto di Immunologia e Patologia presso la Facoltà di Medicina dell'Università degli Studi di Padova, Italia.

ATTIVITÀ ISTITUZIONALE

INSEGNAMENTI

Dal 1989 il prof. Bronte ha insegnato Immunologia, Immunoematologia, Immunopatologia, Patologia Molecolare e Generale come professore a contratto presso la facoltà di Medicina dell'Università degli Studi di Padova. Dal 2011 ha svolto presso l'Università degli Studi di Verona i seguenti insegnamenti come professore ordinario:

- 2011 ad oggi: Immunologia, Corso di Laurea Magistrale a ciclo unico in Medicina e Chirurgia presso l'Università degli Studi di Verona, Italia.
- 2014 ad oggi: Attività Didattica dottorato, Corso di dottorato in Infiammazione, Immunità e Cancro presso l'Università degli Studi di Verona, Italia.
- 2011 - 2017: Introduzione alla Patologia e Immunologia, Laurea in Biotecnologie presso l'Università degli Studi di Verona, Italia.
- 2012 - 2015: Immunologia dei tumori e Immunomodulazione, Corso di Laurea Magistrale, Corso di Laurea Magistrale a ciclo unico in Medicina e Chirurgia presso l'Università degli Studi di Verona, Italia.

RELATORE

TESI DI DOTTORATO

- AA 2018/2019: candidata Francesca Hofer, "*Unveiling the role of DAB2-expressing macrophages in supporting the metastatic spread*", Scuola di Dottorato in Scienze della Vita e della Salute, corso in Infiammazione, Immunità e Cancro presso l'Università degli Studi di Verona, Italia.

- AA 2017/2018: candidata Sara Sartori, "*Tumor-derived exosomes favor immunosuppression and metastatic spread by acting on myeloid cells*", Scuola di Dottorato in Scienze della Vita e della Salute, corso in Infiammazione, Immunità e Cancro presso l'Università degli Studi di Verona, Italia.
- AA 2016/2017: candidata Rosalinda Trovato, "*Identification of potential myeloid cell-related biomarkers of early stage of metastatic process in pancreatic tumor*" Scuola di Dottorato in Scienze della Vita e della Salute, corso in Infiammazione, Immunità e Cancro presso l'Università degli Studi di Verona, Italia.
- AA 2016/2017: candidata Alessandra Fiore, "*Myeloid-derived suppressor cell (MDSC) immunomodulation by c-FLIP*", Scuola di Dottorato in Scienze della Vita e della Salute, corso in Infiammazione, Immunità e Cancro presso l'Università degli Studi di Verona, Italia.
- AA 2015/2016: candidato Andrielly Henrique Rocha Agnellini, "*The role of nitric oxide in cancer immunotherapy*", Scuola di Dottorato in Oncologia ed Oncologia Chirurgica presso l'Università degli Studi di Padova, Italia.
- AA 2015/2016: candidata Irene Pagliarello, "*Cross-talk between myeloid and mesenchymal stem cells (MSC) in the aged human bone marrow*", Scuola di Dottorato in Scienze Biomediche e Traslazionale presso l'Università degli Studi di Verona, Italia.
- AA 2014/2015: candidata Sara Sandri, "*Targeting telomerase in b-cell chronic lymphocytic leukemia*", corso di Biomedicina Traslazionale presso l'Università degli Studi di Verona, Italia.
- AA 2013/2014: candidata Bianca Cali, "*Cellular communication cancer therapy: targeting Ca²⁺ and No signalling within the tumor microenvironment*", Scuola di Dottorato in Oncologia ed Oncologia Chirurgica presso l'Università degli Studi di Padova, Italia.
- AA 2013/2014: candidata Maria Stella Sasso, "*Targeting immunosuppressive myeloid cells using nanocarriers to improve cancer immunotherapy*", Scuola di Dottorato in Oncologia ed Oncologia Chirurgica presso l'Università degli Studi di Padova, Italia.
- AA 2011/2012: candidato Giacomo Desantis, "*Altered differentiation of tumor-associated monocytes and macrophages following generic ablation of disabled homolog 2 gene*", Scuola di Dottorato in Oncologia ed Oncologia Chirurgica presso l'Università degli Studi di Padova, Italia.

- AA 2010/2011: candidata Serena Zilio, *“Role of Arginase 1 and Nitric Oxide Synthase 2 as enzymatic mediators of the immunosuppressive activity in tumor-infiltrating myeloid derived suppressor cells”*, Scuola di Dottorato in Oncologia ed Oncologia Chirurgica presso l’Università degli Studi di Padova, Italia.
- AA 2009/2010: candidata Francesca Papalini, *“Analisi del programma tollerogenico delle cellule soppressorie di origini mieloidi”*, Scuola di Dottorato in Oncologia ed Oncologia Chirurgica presso l’Università degli Studi di Padova, Italia.
- AA 2009/2010: candidata Elisa Peranzoni. *“Studio dei circuiti di controllo in sottopopolazione di cellule mieloidi soppressive indotte dalla crescita tumorale”*, Scuola di Dottorato in Medicina dello Sviluppo e Scienze della Programmazione, corso in Ematologia ed Immunologia presso l’Università degli Studi di Padova, Italia.
- AA 2008/2009: candidata Ilaria Marigo, *“Il programma tollerogenico delle cellule soppressorie di origine mieloidi dipende dal fattore di trascrizione C/EBPbeta”*, Scuola di Dottorato in Oncologia ed Oncologia Chirurgica presso l’Università degli Studi di Padova, Italia.
- AA 2007/2008: candidato Stefano Ugel, *“Approcci di immunoterapia attiva e passiva basati sull’antigene telomerasi in modelli di carcinogenesi murina”*, Scuola di Dottorato in Oncologia ed Oncologia Chirurgica presso l’Università degli Studi di Padova, Italia.
- AA 2005/2006: candidato Luigi Dolcetti, *“Definizione di marcatori molecolari che caratterizzano le cellule mieloidi soppressorie”*, Scuola di Dottorato in Oncologia ed Oncologia Chirurgica presso l’Università degli Studi di Padova, Italia.
- AA 2001/2002: candidato Paolo Serafini, *“Cellule mieloidi soppressorie: genomica funzionale e analisi molecolare del meccanismo di soppressione”*, Scuola di Dottorato in Oncologia ed Oncologia Chirurgica presso l’Università degli Studi di Padova, Italia.

TESI DI SPECIALIZZAZIONE

- AA 2005/2006: candidata Ilaria Marigo, *“Proprietà inibitorie sui linfociti T citotossici di una sottopopolazione di monociti infiammatori indotta dal tumore”*, presso la Facoltà di Medicina e Chirurgia, Scuola di Specializzazione in Patologia Clinica presso l’Università degli Studi di Padova, Italia.

- AA 1999/2000: candidata Elisa Apolloni, “*Inibizione della risposta immune cellulo-mediata indotta da cellule mieloidi soppressorie*”, Facoltà di Medicina, Scuola di Specializzazione in Allergologia e Immunologia Clinica - indirizzo di Immunologia Diagnostica - presso l’Università degli Studi di Padova, Italia.

TESI DI LAUREA

- AA 2018/2019: candidato Nicolò Rashidy, “*Caratterizzazione delle cellule MDSC circolanti nei pazienti con tumore pancreatico*”, corso di Laurea Magistrale a ciclo unico in Medicina e Chirurgia presso l’Università degli Studi di Verona, Italia.
- AA 2018/2019: candidato Giacomo Bertelli “*Characterization of circulating myeloid derived suppressor cells in non-small-cell lung carcinoma patients enrolled for check point inhibitor therapy*”, corso di Laurea Magistrale a ciclo unico in Medicina e Chirurgia presso l’Università degli Studi di Verona, Italia.
- AA 2016/2017: candidata Anna Reni, “*Target therapy e immunomodolazione: effetto di esosomi di melanoma sull’attività di cellule mieloidi soppressorie*”, corso di Laurea Magistrale a ciclo unico in Medicina e Chirurgia presso l’Università degli Studi di Verona, Italia.
- AA 2015/2016: candidata Barbara Zerbato “*Ingegnerizzazione di cellule T con un recettore anti-htert per l’immunoterapia adottiva della leucemia linfoblastica acuta*”, corso di Laurea in Biotecnologie presso l’Università degli Studi di Verona, Italia.
- AA 2015/2016: candidata Giulia Barban, “*Ruolo delle cellule soppressorie di origine mieloidi (MDSC) nel promuovere il processo metastatico*”, corso di Laurea Triennale in Biotecnologie presso l’Università degli Studi di Verona, Italia.
- AA 2014/2015: candidato Daniele Pellegrini, “*Verifica dell’efficacia funzionale di Linfociti T trasdotti per l’espressione di un TCR specifico contro l’epitopo NS31406-1415 del virus HCV*”, corso di Laurea in Biotecnologie presso l’Università degli Studi di Verona, Italia.

BORSE DI STUDIO ASSEGNATE

- 2020: borsa di studio di due anni (2020-2022) di 50.000 € finanziata da FIRC-AIRC “*Fellowships for Italy*”, vinta dalla Post-Doc Annalisa Adamo. Titolo: “*Unveiling the*

role of c-FLIP and c-FLIP-expressing immunosuppressive myeloid cells in non-small-cell lung carcinoma".

- 2018: borsa di studio di tre anni (2018-2021) di 90.000 € finanziata da AIRC, "Prof.ssa Elena Valentino", vinta dalla Post-Doc Varvara Petrova. Titolo: "*The role of S100 proteins in exosome-mediated cancer to immune system crosstalk*".
- 2018: borsa di studio di tre anni (2018-2021) di 75.000 € finanziata da FIRC-AIRC, "Guglielmina Lucatello e Gino Mazzega", vinta dalla Post-Doc Rosalinda Trovato. Titolo: "*Unveiling the molecular insights of hot and cold tumors to enhance immunotherapy efficacy in PDAC*".
- 2017: borsa di studio di due anni (2017-2019) di 110.050 € finanziata da AIRC, "Fellowships for abroad" vinta dalla Post-Doc Alessandra Fiore. Titolo: "*Mechanistic dissection of tryptophan metabolism in the pancreatic tumor microenvironment*".
- 2015: borsa di studio di 3 anni (2015-2018) di 75.000 € finanziata da FIRC-AIRC "Guglielmina Lucatello e Gino Mazzega" vinta dalla Post-Doc Sara Sandri. Titolo: "*Validation of the role of DA B-2 protein in the metastatic process*".
- 2013: borsa di studio di tre anni (2013-2016) di 75.000 €. finanziata da AIRC, "Clienti Carrefour", vinta dal Post-Doc Francesco De Sanctis. Titolo: "*Targeting Arg-1 in MDSCs to improve innovative immunotherapeutic approach in pancreatic cancer*".
- 2013: borsa di studio di un anno (2013) di 20.000 € finanziata da AIRC, "Guerrina Massarenti", vinta dal Post-Doc Giacomo DeSantis. Titolo: "*DAB2 is required for correct macrophage differentiation and metastatic spread in tumor-bearing mice*".
- 2009: borsa di studio di tre anni (2009-2011) finanziata da AIRC, vinta dalla Post-Doc Francesca Simonato. Titolo: "*Ruolo dei microRNA nell'immunosoppressione mediata dalle cellule mieloidi soppressorie*".
- 2002: borsa di studio di tre anni (2002-2005) finanziata da NiCOX, vinta dalla Post-Doc Carmela De Santo. Titolo: "*Targeting myeloid derived suppressor cells with Nitro-aspirin*".

COMMISSIONI

- 2019: Presidente di commissione per l'esame finale del corso di Dottorato di ricerca in Medicina Molecolare e Traslazionale presso l'Università degli Studi di Milano, Italia.

- 2019: Presidente di commissione per procedura selettiva per la progressione verticale per un posto di categoria D - Area tecnica, tecnico scientifica ed elaborazione dati, (Cod.2019dpev005), presso l'Università degli Studi di Verona, Italia.
- 2019: Membro della Commissione di valutazione della procedura per la chiamata ai sensi dell'art. 24, comma 5, della legge n. 240 del 30.12.2010 di n.1 posto di Professore Universitario - seconda fascia - SC 06/A2 - Patologia Generale e Patologia Clinica - MED/04 - Patologia Generale presso il Dipartimento di Medicina Sperimentale dell'Università degli Studi di Perugia (sede di Terni), Italia.
- 2018: Membro della Commissione di valutazione per la chiamata, ai sensi dell'art. 18, comma 1, della legge n. 240 del 30.12.2010 di n.1 posto di Professore Universitario - seconda fascia - SC 06/A2 - Patologia Generale e Patologia Clinica - MED/04 - Patologia Generale presso il Dipartimento di Scienze Biomediche (DSB) dell'Università degli Studi di Padova, Italia.
- 2017: Valutatore esterno tesi di Dottorato in Biologia dei Sistemi in Patologie Immunitarie ed Infettive, XXIX ciclo, presso l'Università degli Studi di Perugia, Italia.
- 2016: Membro della Commissione per procedura selettiva per l'assunzione di n. 1 posto di ricercatore a tempo determinato, con regime di impegno a tempo pieno per il settore concorsuale 06/A2 - Patologia Generale e Patologia Clinica (profilo: settore scientifico disciplinare MED/04 - Patologia Generale - ai sensi dell'art. 24, comma 3, lettera a) presso il Dipartimento di Scienze Biomediche (DSB) dell'Università degli Studi di Padova, Italia.
- Valutatore esterno tesi di Dottorato "Immunosuppressive networks in cancer". Altered myeloid differentiation and immune dysfunctions in cancer. From tumor immunology to immune therapy of cancer (course n. 1594).

ALTRE ATTIVITÀ ISTITUZIONALI

- 01/09/2020 – ad oggi: Presidente CEVS attività accreditamento iniziale Scuola Superiore Sant'Anna di Pisa, Italia.
- 01/11/2019 - ad oggi: co-delegato alla Progettazione e sviluppo della ricerca presso l'Università degli Studi di Verona, Italia.

- 01/01/2014 – ad oggi: Membro del Comitato Tecnico Scientifico del Centro Interdipartimentale di Servizio alla Ricerca Sperimentale (CIRSAL) dell'Università degli Studi di Verona, Italia.
- 01-01-2014 – ad oggi: Componente del Collegio dei Docenti della Scuola di Dottorato in Scienze della Vita e della Salute, corso "Infiammazione, Immunità e Cancro", presso l'Università degli Studi di Verona, Italia.
- 01/01/2011 – ad oggi: Componente del Collegio Didattico del corso di Laurea in Medicina e Chirurgia presso l'Università degli Studi di Verona, Italia.

TERZA MISSIONE

1. RASSEGNA STAMPA

- 25/07/2020: testata giornalistica "L'Arena", titolo: "*Una proteina può impedire la metastasi*", pag. 11, articolo.
- 25/07/2020: approfondimento televisivo "Sky Tg24", titolo: "*Tumori, scoperta una proteina che può predire la comparsa di metastasi*", servizio.
- 24/07/2020: testata giornalistica "Ansa.it - Salute&Benessere", titolo: "*Tumori, una proteina può predire comparsa metastasi*", articolo.
- 24/07/2020: testata giornalistica "La Repubblica", titolo: "*Una proteina ha un ruolo chiave nella formazione di metastasi*", articolo.
- 28/03/2020: testata giornalistica "La Repubblica", titolo: "*Vitamina D contro il Corona Virus? Solo un'ipotesi*", articolo.
- 21/03/2020: testata giornalistica "L'Arena", titolo: "*Si muove anche la ricerca, due milioni da Cariverona*", estratto da pag. 12, articolo.
- 21/03/2020: testata giornalistica "Corriere del Veneto", titolo: "*L'immunologia di Verona: uno studio sugli effetti del Coronavirus*", articolo.
- 11/10/2019: testata giornalistica "Benessere, la salute con l'anima", titolo: "*Una proteina ci tradisce e aiuta il tumore a crescere*", estratto da pag. 8, articolo.
- 11/10/2019: testata giornalistica "La Cronaca di Verona e del Veneto", titolo: "*Laurea ad honorem al premio Nobel per la medicina*", estratto da pag. 8, articolo.
- 11/10/2019: testata giornalistica "L'Arena", titolo: "*Laurea Honoris Causa in medicina al Nobel James Patrick Allison*", estratto da pag. 17, Foglio 1/1, articolo.

- 11/10/2019: testata giornalistica “Corriere di Verona”, titolo: “*Il premio Nobel: sconfiggere il cancro si può*”, estratto da pag. 7, Foglio 1/1, articolo.
- 06/12/2018: testata giornalistica “Gazzettino”, titolo: “*Scoperta delle Università venete contro i tumori e la celiachia*”, estratto da pag. 15, Foglio 1/1, articolo.
- 06/12/2018: testata giornalistica “Corriere di Verona”, titolo: “*Dall’eccellenza universitaria la nuova arma anti-tumore. Lotta ai tumori, identificata la molecola che ostacola l’efficacia delle terapie*”, estratto da pagg. 1-6, Foglio 1/2, articolo.
- 06/12/2018: testata giornalistica “Cronaca di Verona e del Veneto”, titolo: “*Identificata una molecola, ostacola la cura dei tumori*”, estratto da pag. 10, Foglio: 1/1, articolo.
- 06/12/2018: testata giornalistica “Arena”, titolo: “*Da Verona una nuova frontiera nella lotta contro il cancro*”, estratto da pag. 14, Foglio: 1/1, articolo.
- 03/10/2018: testata giornalistica “Corriere del Veneto”, titolo: “*Allison, premio Nobel texano che ama il blues*”, articolo.

2. RASSEGNA TV

- 11/03/2021: Sky Tg24 - Tg pomeridiano, intervista sul tema Covid-19
- 04/02/2021: Sky Tg24 - Tg pomeridiano, intervista sul tema Covid-19
- 27/01/2021: Sky Tg24 - Tg pomeridiano, intervista sul tema Covid-19
- 13/01/2021: TG 3 - Regionale (Veneto): intervista: gli effetti del Covid-19 nel lungo periodo.
- 09/01/2021: Telenuovo - Tg pomeridiano, intervista sul tema Covid-19.
- 23/12/2020: Sky Tg24 - Tg pomeridiano, intervista sul tema Covid-19.
- 14/05/2020: Telenuovo - Tg mattino, intervista.
- 01/04/2020: Telenuovo - Tg Verona 20:30 - dichiarazione del prof. Bronte: “*ottimista ma con attenzione*”, intervista.
- 08/11/2019: Uno Mattina - Rai Uno 08:42 - “*L’immunoterapia del cancro: ne parla il Prof. Vincenzo Bronte, docente universitario e direttore dell’unità operativa complessa di Immunologia presso l’azienda ospedaliera universitaria integrata di Verona*”, intervista.
- 10/10/2019: Telenuovo - Tg Verona 20:41 - “*Il premio Nobel per la medicina James P. Allison è ospite in questi giorni all’Università di Verona*”, servizio.

- 10/10/2019: Tele Arena - Tg Arena 19:42 - *“All’Università di Verona è stato insignito della laurea honoris causa il Nobel per la medicina James Patrick Allison”*, servizio.
- 05/12/2018: Telenuovo - Tg Verona 19:15 - *“Importante scoperta medica all’Università degli Studi di Verona”*, servizio.
- 05/12/2018: Tele Arena - Tg Arena 19:30 - *“Un passo avanti nella lotta contro il cancro”*, servizio.

3. RASSEGNA RADIO

- 05/01/2021: Radio Capital - intervista sul tema Covid-19.
- 06/11/2019: Radio 3 Scienza - 11:00 - *“I giorni della Ricerca”*.
- 05/12/2018: Rai Radio Uno Veneto - Gr1 Veneto - 18:30 - *“Le nuove frontiere della medicina a Verona”*.
- 05/12/2018: Radio Verona - Gr - 19:45 - *“Nuove frontiere nella lotta al cancro”*.
- 05/12/2018: Radio Verona - Gr - 14:00 - *“Identificata molecola che ostacola l’efficacia delle terapie per la cura dei tumori”*.

4. ALTRO

- 09/05/2019: Relatore al “Galileo Festival”, titolo: *“Le frontiere della ricerca sul cancro. Genomica, immunologia, metabolismo, oncologia computazionale”*, Padova, Italia.
- 16/04/2019: Partecipazione al progetto “AIRC nelle scuole”, presso l’Istituto Comprensivo Corvi di Canneto (MN), Italia.
- 04/02/2019: Relatore all’ “Univax Day”, titolo: *“Come funziona il sistema immunitario”*, presso l’Università degli Studi di Verona, Italia.

ATTIVITÀ ASSISTENZIALE

- 2011 ad oggi: Direttore UOC di Immunologia afferente al DAI di Patologia e Diagnostica presso l’Azienda Ospedaliera Universitaria Integrata di Verona, Italia.

Le attività diagnostiche di laboratorio sono svolte per settori di indagine: allergologia, autoimmunità organo specifica e sistemica, analisi delle popolazioni linfocitarie. La scelta degli strumenti e le procedure analitiche utilizzate sono frutto di attente valutazioni da parte del personale responsabile dei vari settori, al fine di assicurare la massima efficienza. Le procedure analitiche sono soggette a regole di standardizzazione, controlli interni di qualità e verifiche esterne di qualità. L'attività ambulatoriale specialistica in allergologia e immunologia clinica per utenti esterni è rivolta alla diagnosi e al trattamento delle malattie allergiche, immunodeficienze primarie, malattia celiaca e intolleranze alimentari. Inoltre, viene effettuata attività di consulenza pre- e post-vaccinale dal Programma Regionale "Canale Verde". L'UOC applica il sistema di gestione "Qualità" conforme alla norma ISO 9001:2015, certificato nell'ambito del Sistema di Gestione dell'Azienda Ospedaliera Universitaria Integrata di Verona dal 10/12/2002 con certificato n°7882/02/S, riconfermato il 27/04/2018, con certificato n°194114/P3. L'UOC di Immunologia si configura come un servizio specialistico con personale misto, ospedaliero e universitario, che eroga prestazioni di laboratorio e ambulatoriali.

- 2010 - 2011: Dirigente medico a rapporto esclusivo, incarico di direzione di struttura semplice, disciplina anatomia patologica a tempo indeterminato, con rapporto di lavoro a tempo unico presso l'Azienda Ospedaliera di Padova, Italia.
- 2004 - 2010: Dirigente medico a rapporto esclusivo, incarico di alta professionalità, disciplina anatomia patologica a tempo indeterminato, con rapporto di lavoro a tempo unico presso l'Azienda Ospedaliera di Padova, Italia.
- 1999 - 2004: Dirigente medico a rapporto esclusivo, disciplina anatomia patologica a tempo indeterminato, con rapporto di lavoro a tempo unico presso l'Azienda Ospedaliera di Padova, Italia.
- 1998 - 1999: Dirigente medico I livello, assistente medico Ex art. 117, disciplina anatomia patologica a tempo indeterminato, con rapporto di lavoro a tempo unico presso l'Azienda Ospedaliera di Padova, Italia.
- 1996 - 1998: Dirigente medico I livello, assistente medico, disciplina anatomia e istologia patologica a tempo indeterminato, con rapporto di lavoro a tempo unico presso l'Azienda Ospedaliera di Padova, Italia.

- 1993 - 1996: Primo livello dirigenziale, fascia sub B, assistente medico, disciplina anatomia e istologia patologica a tempo indeterminato, con rapporto di lavoro a tempo pieno presso l'Azienda Ospedaliera di Padova, Italia.
- 1992 - 1993: Assistente medico, disciplina anatomia e istologia patologica a tempo indeterminato, con rapporto di lavoro a tempo pieno presso l'Azienda Ospedaliera di Padova, Italia.

COMMISSIONI EDITORIALI

- 2020: Cancer Research - Section Editor.
- 2017: Cell Stress.
- 2014: Frontiers in Oncology.
- 2013: Cancer Immunology Research, Section Editor.
- 2013: Journal of Immunology - Section Editor.
- 2011: Frontiers in Tumor Immunity.
- 2010: Journal of Immunology - Section Editor.
- 2009: Journal of Clinical Investigation - Consulting Editor.
- 2003: Journal of Translational Medicine.
- 2001: Current Gene Therapy

GUEST EDITOR

- Febbraio 2018: Seminars in Immunology: coordinatore dell'edizione intitolata "*The Mesenchymal and myeloid regulation of immunity*", Vol. 35, pagg. 1-80.

CONSIGLI SOCIETARI ED ORGANIZZAZIONE CONGRESSI

- 2018: Consigliere del consiglio direttivo del *Network Italiano per la BioTerapia dei Tumor*, (NIBIT).
- 2018: Componente del Comitato Scientifico organizzativo per il 32° congresso annuale dell'*European Macrophage and Dendritic Cell Society*, (EMDS) - "*The cross talk between macrophages and dendritic cells: from immunometabolism to single cell fate*", 27 - 29 Settembre, Verona, Italia.

- 2016: Membro eletto dell'*European Academy for Tumor Immunology*, (EATI).
- 2016: Membro del Comitato Scientifico Locale del 58° incontro annuale della *Società Italiana di Ricerca sul Cancro*, (SIC): "*Revolutionary Road. Accelerating conversion of cancer biology into personalized clinical oncology*", 5 - 8 Settembre, Verona, Italia.
- 2016: Membro del Comitato Internazionale del *Society for Immunotherapy of Cancer* (SITC) e organizzatore del congresso "*Regulatory Myeloid Suppressor Cells Conference*", 16 - 19 Giugno, Philadelphia, PA, USA.
- 2015: Membro del *Cancer Immunotherapy Fellowships Awards* e dell'*Immune Biomarkers Task Force dell'International Society for Immunotherapy of Cancer*, (SITC).
- 2013: Membro della Commissione del Consiglio Scientifico del 15° Congresso Internazionale di Immunologia, Milano, Italia.
- 2012: Consigliere del Comitato Scientifico del *Corso Avanzato di Citometria a Flusso - Applicazioni in Oncologia e Immunologia*, Verona, Italia.
- 2009: Consiglio dei Direttori del *Cancer Italian Society*, (SIC).
- 2008: Membro della Commissione dei Consiglieri Scientifici *dell'Accademia Nazionale di Medicina*.

SCIENTIFIC BOARD

- 2018: Componente del Comitato Tecnico Scientifico IRCCS Sacro Cuore - Don Calabria di Negrar, Verona, Italia.
- 2017: Membro del comitato consultivo della Fondazione Pisana per la Scienza, (FPS), Pisa, Italia.

ALBO

- 2019: Componente "Esperti di Valutazione" dell'ANVUR per la valutazione delle Scuole Superiori a Ordinamento Speciale.

FINANZIAMENTI

- Horizon 2020. “*MR imaging biomarkers of immune response in glioblastoma*”, (2020-2023), 264.500 € (2020, under evaluation, pending).
- Ministero della Salute. Progetto ordinario di ricerca finalizzata: “*An integrative approach to identify immune suppressive features in glioma patients*”, Responsabile Unità Operativa 3, PI Susanna Mandruzzato. (2019-2022), 109.000 € su un totale di 269.900 €.
- Fondazione TIM. Co-finanziamento di progetto ENACT: task force “*Immunovid*”. (2020-2022), 250.000 €.
- Fondazione Cariverona. Progetto: “*Alleanza contro il Covid-19 (ENACT)*”. Coordinatore del progetto e responsabile del sottoprogetto. (2020-2022), 750.000 € su un totale di 2.000.000 €.
- Cancer Research Institute Clinic and Laboratory Integration Program (CLIP) Grant. Progetto: “*CHARON - Claudins Help the ARest of cytotoxic T lymphocytes in tumOrs improving immunotherapy*”, (2020-2022), 196.000 \$. (Coordinatore).
- Associazione Italiana per la Ricerca sul Cancro (AIRC). “*TrainEd MonocytoPoiesis in cancer progression (TEMPO)*”. Codice progetto: IG-23788, (2020-2025), 1.093.00 €.
- Ministero dell’Istruzione, dell’Università e della Ricerca (MIUR). Progetto: “*Deciphering the molecular and functional heterogeneity of myeloid cells in cancer*”. Progetto PRIN 2017, CUP: B38D19000260006, (2019-2022), 185.898 €.
- EU Grant, Euro NanoMed III - 2016. Progetto: “*RESOLVE - supPRESSion of immunopathology by nanOparticle deLiVEry of mRNA to monocytes*”. (2018-2021), 178.710,70 €.
- Fondazione Cariverona. Progetto: “*Analisi e caratterizzazione delle cellule mieloidi in neoplasie solide ed ematologiche*”. (2018-2020), 120.000 €.
- Cancer Research Institute Clinic and Laboratory Integration Program (CLIP) Grant. Progetto: “*Neutralizing human arginase to enhance cancer immunotherapy*”. (2017-2019), 192.000 \$.
- Associazione Italiana per la Ricerca sul Cancro (AIRC). Progetto: “*Innovative tools for early diagnosis and risk assessment of pancreatic cancer*”. Codice progetto: Multi Unit extension AIRC 5x1000 - 12182, (2011-2017), 284.090 €.

- Associazione Italiana per la Ricerca sul Cancro (AIRC). Progetto: “Exosome - driven antiviral response in the metastatic dissemination of pancreatic cancer”. Codice progetto: IG - 18603, (2017-2019), 634.000 €.
- Ministero della Salute. Progetto: “*Investigation of the role of extracellular ATP and the P2X7 receptor in the modulation of immunosuppression within tumour microenvironment*”. Progetto finalizzato, codice CUP: E35G14000190001, (2014-2017), 230.000 €.
- Associazione Italiana per la Ricerca sul Cancro (AIRC). Progetto: “*AREA 2 - An integrated approach to chronic lymphoproliferative disorders: B - CLL and virus - related neoplasia*”. Codice progetto: Multi Unit Regional - 6599, (2013-2015), 124.000 €.
- Associazione Italiana per la Ricerca sul Cancro (AIRC). Progetto: “*Molecular control of the metastatic process by adaptive and innate immunity*”. Codice progetto: IG - 14103, (2014-2017), 530.000 €.
- EU Grant, 7th Framework Programme. Progetto: “*New Oral Nanomedicines - transporting therapeutic macromolecules across the intestinal barrier (acronym: Trans - int)*”, (2012-2017), 301.400 €.
- Ministero dell’Istruzione, dell’Università e della Ricerca (MIUR). Progetto: “*RNA e nanotecnologie del controllo dell’immunosoppressione neoplastica sostenuta da catabolismo degli aminoacidi - RNA and nanotechnology for the control of cancer-dependent immunosuppression by amino acid catabolism*”. Progetto FIRB, codice CUP: B31J11000420001, (2012-2015), 460.400 €.
- Fondazione della Cassa di Risparmio di Padova e Rovigo. Progetto: “*Immunotherapy of prostate cancer: promises and limitations*”, (2012-2014), 1.500.000 €.
- Associazione Italiana per la Ricerca sul Cancro (AIRC). Progetto: “*Reprogramming tumor environment to increase the effectiveness of cancer immunotherapy*”. Codice progetto: IG - 10400, (2011-2014), 390.000 €.
- Associazione Italiana per la Ricerca sul Cancro (AIRC). Progetto: “*Innovative tools for early diagnosis and risk assessment of pancreatic cancer immunotherapy*”. Codice progetto: Multi Unit AIRC 5x1000 - 12182, (2011-2017), 961.636,50 €.
- Associazione Italiana per la Ricerca sul Cancro (AIRC). Progetto: “*AREA 2 - An integrated approach to chronic lymphoproliferative disorder: B - CLL and virus -*

- related neoplasia*". Codice progetto: Multi Unit Regional - 659, (2009-2012), 400.000 €.
- EU Grant, Euronamed call. Progetto: "*Lymphonanocarriers for the treatment of metastatic cancer*", (2010-2012), 200.000 €.
 - Università degli Studi di Padova. Progetto: "*Role of arginase 1 in tumor promotion and induction of tumor - associated immune dysfunctions*", (2009-2010), 71.000 €.
 - Fondazione della Cassa di Risparmio di Padova e Rovigo. Progetto: "*Myeloid - derived suppressor cells in chronic inflammation and cancer*", (2008-2010), 420.000 €.
 - Ricerca Oncologica 2006, Progetto ex art. 12 Ministero, Prot. N° 381143/50.00.034. Progetto: "*Identification of novel molecular targets in pancreatic cancer by analysis of tumor - stroma interaction*", (2009-2010), 148.000 €.
 - Programma Integrato per la Ricerca Oncologica, Ministero della Salute, n. RO Strategici 8/07. Progetto: "*Microambiente tumorale: ruolo nella progressione neoplastica ed effetti sulle difese dell'ospite. Identificazione di nuovi bersagli per lo sviluppo di terapie innovative*", (2008-2011), 145.000 €.
 - Association for International Cancer Research, U.K. Progetto: "*Evaluating the role of arginase 1 in tumor development and tumor-induced tolerance*", (2008-2010), 138.000 €.
 - Italia - U.S. program, Istituto Superiore di Sanità, Contratto 527/A/3A/1. Progetto: "*Micro - RNA in haematological cancers: a high - throughput approach based on tissue - specific microRNA libraries*", (2007-2008), 250.000 €.
 - Istituto Superiore per l'Alleanza Contro il Cancro, programma per la ricerca oncologica. "Rete solidale e collaborazioni internazionali" (DM del 21/07/2006, art. 3, ISS per ACC). Progetto: "*Development of new drugs restoring antitumor immune response by altering tumor microenvironment*", (2007-2009), 1.200.000 €.
 - Italia - Quebec program for scientific cooperation and technology development. Progetto: "*Metabolome and transcriptome analysis of tumor microenvironment - from pathogenetic mechanisms to marker discovery*", (2006-2008).

- U.S. Department of Defence (ARMY). Progetto: “*Defining novel molecules to rescue immunity against prostate cancer - molecular and biological bases for new therapies*”, (2006-2008), 432.000 \$.
- Fondazione Italiana Sclerosi Multipla ONLUS (FISM). Progetto: “*Myeloid suppressor cells as a novel regulatory population to restrain autoimmune aggression in multiple sclerosis*”, (2006-2008), 68.000 €.
- Associazione Italiana per la Ricerca sul Cancro (AIRC). Progetto: “*MicroRNA in haematological cancers: a high - throughput approach based on tissue - specific microRNA libraries*”. Codice progetto: IG - 4175, 600.000 €
- Istituto Superiore Sanità (contratto 530/F - A3). Progetto: “*Use of novel drugs affecting L - arginine metabolism in myeloid suppressor cells ad adjuvant of adoptive cancer immunotherapy*”, (2004-2005), 50.000 €.
- Coordinatore nazionale del progetto FIRB - MIUR. Progetto: “*Genomic and functional analysis of accessory cells with regulatory activity on immune responses*”. Codice del progetto: RBAU01935A, (2004-2006), 200.000 €.
- Programma Italia - U.S. per la terapia del cancro. Ministero della Sanità, Istituto Superiore di Sanità, accordo di collaborazione scientifica n. T00.A17. Progetto: “*Novel approaches to overcome dysfunction of the immune responses caused by myeloid suppressor cells during neoplastic growth, expression in myeloid cells regulating the function of T lymphocytes*”. Codice: ITL90000000, (2001-2003), 45.000 €.

PUBBLICAZIONI

1. Bost P, De Sanctis F, Canè S, Ugel S, Donadello K, Castellucci M, Eyal D, Fiore A, Anselmi C, Barouni RM, Trovato R, Caligola S, Lamolinara A, Iezzi M, Facciotti F, Mazzariol A, Gibellini D, De Nardo P, Tacconelli E, Gottin L, Polati E, Schwikowski B, Amit I, **Bronte V**. Deciphering the state of immune silence in fatal COVID-19 patients. *Nat Commun.* 2021 Mar 5;12(1):1428. doi:10.1038/s41467-021-21702-6.
2. De Sanctis F, **Bronte V**. How to reprogram Myeloma-Associated macrophages: target IKZF1. *Cancer Immunol Res.* 2021 Mar;9(3):254. doi:10.1158/2326-6066.CIR-21-0026.

3. Ugel S, Canè S, De Sanctis F, **Bronte V**. Monocytes in the tumor microenvironment. *Annu Rev Pathol.* 2021 Jan 24;16:93-122. doi: 10.1146/annurev-pathmechdis-012418-013058. PMID: 33497262.
4. Taus F, Salvagno G, Canè S, Fava C, Mazzaferri F, Carrara E, Petrova V, Barouni RM, Dima F, Dalbeni A, Romano S, Poli G, Benati M, Denitto S, Mansueto G, Iezzi M, Tacconelli E, Lippi G, **Bronte V**, Minuz P. Platelets promote thromboinflammation in SARS-CoV-2 pneumonia. *Arterioscler Thromb Vasc Biol.* 2020 Dec;40(12):2975-2989. doi: 10.1164/ATVBAHA.120.315175. Epub 2020 Oct 14. PMID: 33052054.

Commentato in:

Megakaryocytes: Masters of Innate Immunity?

Crispin PJ, Montague SJ. *Arterioscler Thromb Vasc Biol.* 2020 Dec;40(12):2812-2814. doi: 10.1161/ATVBAHA.120.315471. Epub 2020 Nov 24. PMID: 33232209

5. **Bronte V**, Ugel S, Tinazzi E, Vella A, De Sanctis F, Canè S, Batani V, Trovato R, Fiore A, Petrova V, Hofer F, Barouni RM, Musiu C, Caligola S, Pinton L, Torroni L, Polati E, Donadello K, Friso S, Pizzolo F, Iezzi M, Facciotti F, Pelicci PG, Righetti D, Bazzoni P, Rampudda M, Comel AC, Mosaner W, Lunardi C, Olivieri O. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. *J Clin Invest.* 2020 Dec 1;130(12):6409-6416. doi:10.1172/JCI141772. PMID: 32809969.

Commentato in:

Caring for patients in a new pandemic: the necessity and challenges of observational research.

Thomas DL. *J Clin Invest.* 2020 Dec 1;130(12):6225-6227. doi: 10.1172/JCI143292. PMID: 32902413

6. Marigo I, Trovato R, Hofer F, Ingangi V, De Sanctis F, Ugel s, Canè S, Simonelli A, Lamolinara A, Iezzi M, Fassan M, Ruggie M, Boschi F, Borile G, Eisenhaure T, Sarkizova S, Lieb D, Hacoheh N, Azzolin L, Piccolo S, Lawlor RT, Scarpa A, Carbogni L, Bria E, Bicciato S, Murray PJ, **Bronte V**. Disabled homolog 2 controls prometastatic activity of tumor-associated macrophages. *Cancer Discov.* 2020 Nov;10(11):1758-1773. doi:10.1158/2159-8290.CD-20.0036. Epub 2020 Jul 10. PMID: 32651166.
7. Croce M, Damonte P, Morini M, Pigozzi S, Chiossone L, Vacca P, **Bronte V**,

- Barbieri O, Astigiano S. Increased Arginase1 expression in tumor microenvironment promotes mammary carcinogenesis via multiple mechanisms. *Carcinogenesis*. 2020 Dec 31;41(12):1695-1702. doi:10.1093/carcin/bgaa063. PMID: 32614387.
8. Cancio M, Ciccocioppo R, Rocco PRM, Levine BL, **Bronte V**, Bollard CM, Weed D, Boelens JJ, Hanley PJ. Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies. *Cytotherapy*. 2020 Sep;22(9):474-481. doi:10.1016/j.cyt.2020.04.100. Epub 2020 May 7. PMID: 32565132.
 9. De La Fuente A, Zilio S, Caroli J, Van Simaey D, Mazza EMC, Ince TA, **Bronte V**, Bicciato S, Weed DT, Serafini P. Aptamers against mouse and human tumor-infiltrating myeloid cells as reagents for targeted chemotherapy. *Sci Transl Med*. 2020 Jun 17;12(548):eaav9760. doi:10.1126/scietranslmed.aav9760. PMID: 32554710.
 10. Porta C, Consonni FM, Morlacchi S, Sangaletti S, Bleve A, Totaro MG, Larghi P, Rimoldi M, Tripodo C, Strauss L, Banfi S, Storto M, Pressani T, Rimassa L, Tartari S, Ippolito A, Doni A, Soldà G, Duga S, Piccolo V, Ostuni R, Natoli G, **Bronte V**, Balzac F, Turco E, Hirsch E, Colombo MP, Sica A. Tumor-derived prostaglandin E2 promotes p50 NF- κ B-dependent differentiation of monocytic MDSCs. *Cancer Res*. 2020 Jul 1;80(13):2874-2888. doi: 10.1158/0008-5472.CAN-19-2843. Epub 2020 Apr 7. PMID: 32265223.
 11. Vella A, D'Aversa E, Api M, Breveglieri G, Allegri M, Giacomazzi A, Busilacchi EM, Fabrizzi B, Cestari T, Sorio C, Bedini G, D'Amico G, **Bronte V**, Poloni A, Benedetti A, Bovo C, Corey SJ, Borgatti M, Cipolli M, Bezzerri V. mTOR and STAT3 pathway hyper-activation is associated with elevated Interleukin-6 levels in patients with Shwachman-Diamond Syndrome: further evidence of Lymphoid Lineage Impairment. *Cancers (Basel)*. 2020 Mar 5;12(3):597. doi:10.3390/cancers12030597. PMID:32150944.
 12. Pinton L, Magri S, massetto E, Vettore M, Schibuola I, Ingangi V, Marigo I, Matha K, Benoit JP, Della Puppa A, **Bronte V**, Lollo G, Mandruzzato S. Targeting of immunosuppressive myeloid cells from glioblastoma patients by modulation of size and surface charge of lipid nanocapsules. *J Nanobiotechnology*, 2020 Feb 17;18(1):31. doi:10.1186/s12951-020-00589-3. PMID: 32066449.
 13. **Bronte V**. Macrophages instruct aberrant glycosylation in colon cancer by

chemokine and cytokine signals. *Cancer Immunol Res.* 2020 Feb;8(2):160. doi:10.1158/2326-6066.CIR-19-1005. PMID: 32015012.

Commentato in

Cross-talk between Colon Cells and Macrophages Increases ST6GALNAC1 and MUC1-sTn Expression in Ulcerative Colitis and Colitis-Associated Colon Cancer.

Kvorjak M, Ahmed Y, Miller ML, Sriram R, Coronello C, Hashash JG, Hartman DJ, Telmer CA, Miskov-Zivanov N, Finn OJ, Cascio S. *Cancer Immunol Res.* 2020 Feb;8(2):167-178. doi: 10.1158/2326-6066.CIR-19-0514. Epub 2019 Dec 12. PMID: 31831633

14. Halaby MJ, Hezaveh K, Lamorte S, Ciudad MT, Kloetgen A, MacLeod BL, Guo M, Chakravarthy A, Medina TDS, Ugel S, Tsigos A, **Bronte V**, Munn DH, Pugh TJ, De Carvalho DD, Butler MO, Ohi PS, Brooks DG, McGaha TL. GCN2 drives macrophages and MDSC function and immunosuppression in the tumor microenvironment. *Sci Immunol.* 2019 Dec 13;4(45):eaax8189. doi:10.1126/sciimmunol.aax8189. PMID: 31836669.

15. **Bronte V**. Close to the bone; tissue-specific checkpoint immunotherapy evasion. *Cell.* 2019 Nov 14;179(5):1010-1012. doi:10.1016/j.cell.2019.10.022. PMID: 31730845.

Commentato in:

Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy.

Jiao S, Subudhi SK, Aparicio A, Ge Z, Guan B, Miura Y, Sharma P. *Cell.* 2019 Nov 14;179(5):1177-1190.e13. doi: 10.1016/j.cell.2019.10.029. PMID: 31730856

16. Jacquelot N, Yamazaki T, Roberti MP, Duong CPM, Andrews MC, Verlingue L, Ferrere G, Becharef S, Vétizou M, Daillère R, Messaoudene M, Enot DP, Stoll G, Ugel S, Marigo I, Foong Ngiow S, Marabelle A, Prevost-Blondel A, Gaudreau PO, Gopalakrishnan V, Eggermont AM, Opolon P, Klein C, Madonna G, Ascierto PA, Sucker A, Schadendorf D, Smith MJ, Soria JC, Kroemer G, **Bronte V**, Wargo J, Zitvogel L. Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. *Cell Res.* 2019 Oct 29;(10):846-861. doi:10.1038/s41422-019-0224-x. Epub 2019 Sep 3. PMID: 31481761.

17. Trovato R, Fiore A, Sartori S, Canè S, Giugno R, Cascione L, Paiella S, Salvia

- R, De Sanctis F, Poffe O, Anselmi C, Hofer F, Sartoris S, Piro G, Carbone C, Corbo V, Lawlor R, Solito S, Pinton L, Mandruzzato S, Bassi C, Scarpa A, **Bronte V**, Ugel S. Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3. *J Immunother Cancer*. 2019 Sep 18;7(1):255. doi:10.1186/s40425-019-0734-6. PMID: 31533831.
18. Koehn BH, Saha A, McDonald-Hyman C, Loschi M, Thangavelu G, Ma L, Zaiken M, Dysthe J, Krepps W, Panthera J, Hippen K, Jameson SC, Miller JS, Cooper MA, Farady CJ, Iwawaki T, Ting JP, Serody Js, Murphy WJ, Hill GR, Murray PJ, **Bronte V**, Munn DH, Zaiser R, Blazar BR. Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GvHD. *Blood*. 2019 Nov 7;134(19):1670-1682. doi:10.1182/blood.2019001950. PMID: 31533918.
- Commentato in:
- We didn't start the fire, MDSC inflammasome signaling in GVHD.**
Buxbaum NP. *Blood*. 2019 Nov 7;134(19):1570-1572. doi:10.1182/blood.2019003247. PMID: 31698421
19. Filippini D, Agosto S, Delfino P, Simbolo M, Piro G, Rusev B, Veghini L, Cantù C, Lupo F, Ugel S, De Sanctis F, **Bronte V**, Milella M, Tortora G, Scarpa A, Carbone C, Corbo V. Immuno-evolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease. *Sci Rep*. 2019 Aug 22;9(1):12286. doi:10.1038/s41598-019-48663-7. PMID: 31439856.
20. Canè S, Ugel S, Trovato R, Marigo I, De Sanctis F, Sartoris S, **Bronte V**. The Endless Saga of Monocyte Diversity. *Front Immunol*. 2019 Aug 6;10:1786. doi:10.3389/fimmu.2019.01786. eCollection 2019. PMID: 31447834.
21. Fleming V, Hu X, Weller C, Weber R, Groth C, Riester Z, Hüser L, Sun Q, Nagibin V, Kirschning C, **Bronte V**, Utikal J, Altevog P, Umansky V. Melanoma extracellular vesicles generate immunosuppressive myeloid cells by upregulating PD-L1 via TLR4 signaling. *Cancer Res*. 2019 Sep 15; 79(18):4715-4728. doi:10.1158/0008-5472.CAN-19-0053. Epub 2019 Jul 23. PMID: 31337655.
22. **Bronte V**. Deciphering macrophage and monocyte code to stratify human breast cancer patients. *Cancer Cell*. 2019 Apr 15;35(4):538-539. doi:10.1016/j.ccell.2019.03.010. PMID: 30991022.
- Commentato in:

Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets.

- Cassetta L, Fragkogianni S, Sims AH, Swierczak A, Forrester LM, Zhang H, Soong DYH, Cotechini T, Anur P, Lin EY, Fidanza A, Lopez-Yrigoyen M, Millar MR, Urman A, Ai Z, Spellman PT, Hwang ES, Dixon JM, Wiechmann L, Coussens LM, Smith HO, Pollard JW. *Cancer Cell*. 2019 Apr 15;35(4):588-602.e10. doi: 10.1016/j.ccell.2019.02.009. Epub 2019 Mar 28. PMID: 30930117
23. Bertelli G, Trovato R, Ugel S, Bria E, Milella M, **Bronte V**, Pilotto S. Characterization of myeloid-derived suppressor cells in a patient with lung adenocarcinoma undergoing durvalumab treatment: a case report. *Clin Lung Cancer*. 2019 Jul 20;(4):e514-e516. doi:10.1016/j.clc.2019.04.013. Epub 2019 Apr 28. PMID: 31122866.
24. Solito S, Pinton L, De Sanctis F, Ugel S, **Bronte V**, Mandruzzato S, Marigo I. Methods to measure MDSC immune suppressive activity in vitro and in vivo. *Curr Protoco Immunol*. 2019 Feb;124(1):e61. doi:10.1002/cpim.61. Epub 2018 Oct 10. PMID: 30303619.
25. Travelli C, Consonni FM, Sangaletti S, Storto M, Morlacchi S, Grolla AA, Galli U, Tron GC, Portararo P, Rimassa L, Pressiani T, Mazzone M, Trovato R, Ugel S, **Bronte V**, Tripodo C, Colombo MP, Genazzani AA, Sica A. Nicotinamide phosphoribosyltransferase (NAMPT) acts as a metabolic gate for mobilization of myeloid-derived suppressor cells. *Cancer Res*. 2019 Apr 15;79(8):1938-1951. doi:10.1158/0008-5472.CAN-18-1544. Epub 2019 Feb 18. PMID: 30777853.
26. Ledo AM, Sasso MS, **Bronte V**, Marigo I, Boyd BJ, Garcia-Fuentes M, Alonso MJ. Co-delivery of RNAi and chemokine by polyarginine nanocapsules enables the modulation of myeloid-derived suppressor cells. *J Control Release*. 2019 Feb 10;295:60-73. doi:10.1016/j.conrel.2018.12.041. Epub 2018 Dec 26. PMID: 30593832.
27. Bezzerri V, Vella A, Di Gennaro G, Ortolani R, Nicolis E, Cesaro S, Fabrizzi B, **Bronte V**, Corey SJ, Cipolli M. Peripheral blood immunophenotyping in a large cohort of patients with Shwachman-Diamond syndrome. *Pediatr Blood Cancer*. 2019 May;66(5):e27597. doi:10.1002/pbc.27597. Epub 2019 Jan 2. PMID: 30604473.
28. Fiore A, Ugel S, De Sanctis F, Sandri S, Fracasso G, Trovato R, Sartoris S, Solito

S, Mandruzzato S, Vascotto F, Hippen KL, Mondanelli G, Grohmann U, Piro G, Carbone C, Melisi D, Lawlor RT, Scarpa A, Lamolinara A, Iezzi M, Fassan M, Biciato S, Blazar BR, Sahin U, Murray PJ, **Bronte V**. Induction of immunosuppressive functions and NF- κ B by FLIP in monocytes. *Nat. Commun.* 2018 Dec 5;9(1):5193. doi:10.1038/s41467-018-07654-4. PMID: 30518925.

29. **Bronte V**. The expanding constellation of immune checkpoints: a DNAMic control by CD155. *J Clin Invest.* 2018 Jun 1;128(6):2199-2201. doi:10.1172/JCI121229. Epub 2018 May 14. PMID: 29757194.

Commentato in:

CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms.

Li XY, Das I, Lepletier A, Addala V, Bald T, Stannard K, Barkauskas D, Liu J, Aguilera AR, Takeda K, Braun M, Nakamura K, Jacquelin S, Lane SW, Teng MW, Dougall WC, Smyth MJ. *J Clin Invest.* 2018 Jun 1;128(6):2613-2625. doi: 10.1172/JCI98769. Epub 2018 May 14. PMID: 29757192

30. **Bronte V**. The mesenchymal and myeloid regulation of immunity: power is nothing without control. *Semin Immunol.* 2018 Feb;35:1-2. doi:10.1016/j.smim.2018.03.001. PMID: 29566937.

31. Sharma MD, Rodriguez PC, Koehn BH, Baban B, Cui Y, Guo G, Shimoda M, Pacholczyk R, Shi H, Lee EJ, Xu H, Johnson TS, He Y, Mergoub T, Venable C, **Bronte V**, Wolchok JD, Blazar BR, Munn DH. Activation of p53 in myeloid precursor cells controls differentiation into immunogenic Ly6c+CD103+monocytic cells in tumors. *Immunity.* 2018 Jan 16;48(1):91-106.e6. doi:10.1016/j.immuni.2017.12.014. PMID: 29343444.

Commentato in:

moDCs, Less Problems.

Gardner A, Ruffell B. *Immunity.* 2018 Jan 16;48(1):6-8. doi: 10.1016/j.immuni.2017.12.017. PMID: 29343441

32. **Bronte V**. From Oncogene interference to neutrophil immune modulation. *Immunity.* 2017 Oct 17;47(4):613-615. doi:10.1016/j.immuni.2017.10.005. PMID: 29045894.

Commentato in:

Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy.

- Glodde N, Bald T, van den Boorn-Konijnenberg D, Nakamura K, O'Donnell JS, Szczepanski S, Brandes M, Eickhoff S, Das I, Shridhar N, Hinze D, Rogava M, van der Sluis TC, Ruotsalainen JJ, Gaffal E, Landsberg J, Ludwig KU, Wilhelm C, Riek-Burchardt M, Müller AJ, Gebhardt C, Scolyer RA, Long GV, Janzen V, Teng MWL, Kastenmüller W, Mazzone M, Smyth MJ, Tüting T, Hölzel M. *Immunity*. 2017 Oct 17;47(4):789-802.e9. doi: 10.1016/j.immuni.2017.09.012. PMID: 2904590.
33. Sandri S, De Sanctis F, Lamolinara A, Boschi F, Poffe O, Trovato R, Fiore A, Sartori S, Sbarbati A, Bondanza A, Cesaro S, Krampers M, Scupoli MT, Nishimura MI, Iezzi M, Sartoris S, **Bronte V**, Ugel S. Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy. *Oncotarget*. 2017 May 23;8(50):86987-87001. doi:10.18632/oncotarget.18115. eCollection 2017 Oct 20. PMID: 29152058.
34. Mondanelli G, Ugel S, Grohmann U, **Bronte V**. The immune regulation in cancer by the amino acid metabolizing enzymes ARG and IDO. *Curr Opin Pharmacol*. 2017 Aug;35:30-39. doi:10.1016/j.coph.2017.05.002. Epub 2017 May 26. PMID: 28554057.
35. Gnjatic S, **Bronte V**, Brunet LR, Butler MO, Disis ML, Galon J, Hakansson LG, Hanks BA, Karanikas V, Khleif SN, Kirkwood JM, Miller LD, Schendel DJ, Tenneau I, Wigginton JM, Butterfield LH. Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. *J Immunother Cancer*. 2017 May 16;5:44. doi:10.1186/s40425-017-0243-4. eCollection 2017. PMID: 28515944.
36. Zilio S, Vella JL, De la Fuente AC, Daftarian PM, Weed DT, Kaifer A, Marigo I, Leone K, **Bronte V**, Serafini P. 4PD functionalized dendrimers: a flexible tool for in vivo gene silencing of tumor-educated myeloid cells. *J Immunol*. 2017 May 15;198(10):4166-4177. doi:10.4049/jimmunol.1600833. Epub 2017 Apr 10. PMID: 28396317.
37. Mondanelli G, Bianchi R, Pallotta MT, Orabona C, Albini E, Iacono A, Belladonna ML, Vacca C, Fallarino F, Macchiarulo A, Ugel S, **Bronte V**, Gevi F, Zolla L, Verhaar A, Peppelenbosch M, Mazza EM, Biciato S, Laouar Y, Santambrogio L, Puccetti P, Volpi C, Grohmann U. A relay pathway between arginine and tryptophan metabolism confers immunosuppressive properties on dendritic cells.

Immunity. 2017 Feb 21;46(2):233-244. doi:10.1016/j.immuni.2017.01.005. Epub 2017 Feb 14. PMID: 28214225.

38. Trento C, Marigo I, Pievani A, Galleu A, Dolcetti L, Wang CY, Serafini M, **Bronte V**, Dazzi F. Bone marrow mesenchymal stromal cells induce nitric oxide synthase-dependent differentiation of CD11b+ cells that expedite hematopoietic recovery. *Haematologica*. 2017 May;102(5):818-825. doi:10.3324/haematol.2016.155390. Epub 2017 Feb 9. PMID: 28183849.
39. Perico ME, Grasso S, Brunelli M, Martigoni G, Munari E, Moiso E, Fracasso G, Cestari T, Naim HY, **Bronte V**, Colombatti M, Ramarli D. Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells “in vitro” and correlating with progression “in vivo”. *Oncotarget*. 2016 Nov 8;7(45):74189-74202. doi:10.18632/oncotarget.1244. PMID: 27713116.
40. Marigo I, Zilio S, Desantis G, Mlecnik B, Agnellini AH, Ugel S, Sasso MS, Qualls JE, Kratochvill F, Zanovello P, Molon B, Ries CH, Runza V, Hoves S, Bilocq AM, Bindea G, Mazza EM, Biccato S, Galon J, Murry PJ, **Bronte V**. T cell cancer therapy requires CD40-CD40L activation of tumor necrosis factor and inducible nitric-oxide-synthase-producing dendritic cells. *Cancer Cell*. 2016 Oct 10;30(4):651. doi:10.1016/j.ccell.2016.09.009. PMID:27728809.

Commentato in:

Tipping the Balancing ACT.

Pilon-Thomas S, Ruffell B. *Cancer Cell*. 2016 Sep 12;30(3):367-368. doi: 10.1016/j.ccell.2016.08.012. PMID: 27622327

41. **Bronte V**, Tortora G. Adipocytes and neutrophils give a helping hand to pancreatic cancers. *Cancer Discov*. 2016 Aug;6(8):821-3. doi:10.1158/2159-8290.CD-16-0682. PMID: 27485002.

Commentato in:

Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy.

Incio J, Liu H, Suboj P, Chin SM, Chen IX, Pinter M, Ng MR, Nia HT, Grahovac J, Kao S, Babykutty S, Huang Y, Jung K, Rahbari NN, Han X, Chauhan VP, Martin JD, Kahn J, Huang P, Desphande V, Michaelson J, Michelakos TP, Ferrone CR, Soares R, Boucher Y, Fukumura D, Jain RK. *Cancer Discov*. 2016 Aug;6(8):852-69. doi: 10.1158/2159-8290.CD-15-1177. Epub 2016 May 31.

PMID: 27246539

42. **Bronte V**, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, Rodriguez PC, Sica A, Umansky V, Vonderheide RH, Gavrillovich DI. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. *Nat Commun.* 2016 Jul 6;7:12150. doi:10.1038/ncomms12150. PMID:27381735.
43. Sandri S, Bobisse S, Moxley K, Lamolinare A, De Sanctis F, Boschi F, Sbarbati A, Fracasso G, Ferrarini G, Hendriks RW, Cavallini C, Scrupoli MT, Sartoris S, Iezzi M, Nishimura MI, **Bronte V**, Ugel S. Feasibility of telomerase-specific adoptive T-cell therapy for B-cell chronic lymphocytic leukemia and solid malignancies. *Cancer Res.* 2016 May 1;76(9):2540-51. doi:10.1158/0008-5472.CAN-15-2318. PMID: 27197263.
44. Sasso MS, Lollo G, Pitorre M, Solito S, Pinton L, Valpione S, Bastiat G, Mandruzzato S, **Bronte V**, Marigo I, Benoit JP. Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy. *Biomaterials.* 2016 Jul;96:47-62. doi:10.1016/j.biomaterials.2016.04.010. Epub 2016 Apr 22. PMID: 27135716.
45. **Bronte V**, Bria E. Interfering with CCL5/CCR5 at the tumor-stroma interface. *Cancer Cell.* 2016 Apr 11;29(4):437-439. doi:10.1016/j.ccell.2016.03.019. PMID: 27070698.
- Commentato in:
- Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients.**
- Halama N, Zoernig I, Berthel A, Kahlert C, Klupp F, Suarez-Carmona M, Suetterlin T, Brand K, Krauss J, Lasitschka F, Lerchl T, Luckner-Minden C, Ulrich A, Koch M, Weitz J, Schneider M, Buechler MW, Zitvogel L, Herrmann T, Benner A, Kunz C, Luecke S, Springfield C, Grabe N, Falk CS, Jaeger D. *Cancer Cell.* 2016 Apr 11;29(4):587-601. doi: 10.1016/j.ccell.2016.03.005. PMID: 27070705.
46. Arina A, Corrales L, **Bronte V**. Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment. *Semin Immunol.* 2016 Feb; 28(1):54-63. doi:10.1016/j.smim.2016.01.02. Epub 2016 Feb 10. PMID: 26872631.
47. Mandruzzato S, Brandau S, Britten CM, **Bronte V**, Damuzzo V, Gouttefangeas

- C, Maurer D, Ottensmeier C, Van Der Burg SH, Welters MJ, Walter S. Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: result from an interim study. *Cancer Immunol Immunother*. 2016 Feb; 65(2):161-9. doi:10.1007/s00262-015-1782-5. Epub 2016 Jan 4. PMID: 26728481.
48. Pinton L, Solito S, Damuzzo V, Francescato S, Pozzuoli A, Berizzi A, Mocellin S, Rossi CR, **Bronte V**, Mandruzzato S. Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression. *Oncotarget* 2016 Jan 12; 7(2):1168-84. doi:10.18632/oncotarget.6662. PMID: 26700461.
49. Munn DH, **Bronte V**. Immune suppressive mechanisms in the tumor microenvironment. *Curr Opin Immunol*. 2016 Apr;39:1-6. doi:10.1016/j.coi.2015.10.009. Epub 2015 Nov 21. PMID: 26609943.
50. Massari F, Ciccarese C, Caliò A, Munari E, Cima L, Porcaro AB, Novella G, Artibani W, Sava T, Eccher A, Ghimenton C, Bertoldo F, Scarpa A, Sperandino N, Porta C, **Bronte V**, Chilosi M, Bogina G, Zamboni G, Tortora G, Samaratunga H, Martignoni G, Brunelli M. Magnitude of PD-1, PD-L1 and T lymphocyte expression on tissue from castration-resistant prostate adenocarcinoma: an exploratory analysis. *Target Oncol*. 2016 Jun;11(3):345-51. doi:10.1007/s11523-015-0396-3. PMID: 26566945.
51. Astigiano S, Morini M, Damonte P, Fraternali Orcioni G, Cassanello M, Puglisi A, Noonan DM, **Bronte V**, Barbieri O. Transgenic Mice overexpressing arginase 1 in monocytic cell lineage are affected by lympho-myeloproliferative disorder and disseminated intravascular coagulation. *Carcinogenesis*. 2015 Nov;36(11):1354-62. doi:10.1093/carcin/bgv129. Epub 2015 Sep 10. PMID: 26363032.
52. Ugel S, De Sanctis F, Mandruzzato S, **Bronte V**. Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. *J Clin Invest*. 2015 Sep;125(9):3365-76. doi:10.1172/JCI80006. Epub 2015 Sep 1. PMID: 26325033.
53. Zhu Z, Cuss SM, Singh V, Gurusamy D, Shoe JL, Leighty R, **Bronte V**, Hurwitz AA. CD4+T cell help selectively enhances high-avidity tumor antigen-specific CD8+T cells. *J Immunol*. 2015 Oct 1;195(7):3482-9. doi:10.4049/jimmunol.1401571. Epub 2015 Aug 28. PMID: 26320256.
54. Ochando J, Conde P, **Bronte V**. Monocyte-derived suppressor cells in

transplantation. *Curr Transplant Rep.* 2015;2(2):176-83. doi:10.1007/s40472-015-0054-9. PMID: 26301174.

55. Koehn BH, Apostolova P, Haverkamp JM, Miller JS, McCullar V, Tolar J, Munn DH, Murphy WJ, Brickey WJ, Serody JS, Gabilovich DI, **Bronte V**, Murray PJ, Ting JP, Zeiser R, Blazar BR. GvHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells. *Blood.* 2015 Sep 24;126(13):1621-8. doi:10.1182/blood-2015-03-634691. Epub 2015 Aug 11. PMID: 26265697.
56. De Sanctis F, Solito S, Ugel S, Molon B, **Bronte V**, Marigo I. MDSCs in cancer: conceiving new prognostic and therapeutic targets. *Biochim Biophys Acta.* 2016 Jan;1865(1):35-48. doi:10.1016/j.bbcan.2015.08.001. Epub 2015 Aug 6. PMID: 26255541.
57. Norman MZ, Janji B, Hu S, Wu JC, Martelli F, **Bronte V**, Chouaib S. Tumor promoting effects of myeloid derived suppressor cells are potentiated by hypoxia-induced expression of miR-210. *Cancer Res.* 2015 Sep 15;75(18):3771-87. doi:10.1158/0008-5472.CAN-15-0405. Epub 2015 Jul 23. PMID: 26206559.
58. Carbognin L, Pilotto S, Milella M, Vaccaro V, Brunelli M, Caliò A, Cuppone F, Sperduti I, Giannarelli D, Chilosi M, **Bronte V**, Scarpa A, Bria E, Tortora G. Differential activity of nivolumab, pembrolizumab and MPDL3208A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. *PLoS One.* 2015 Jun 18; 10(6):e0130142. doi:10.1371/journal.pone.0130142. eCollection 2015. PMID: 26086854.
59. Conde P, Rodriguez M, Van der Touw W, Jiminez A, Burns M, Miller J, Brahmachary M, Chen HM, Boros P, Rausell-Palamos F, Yun TJ, Riquelme P, Rastrojo A, Aguado B, Stein-Streilein J, Tanaka M, Zhou L, Zhang L, Lowary TL, Ginhoux F, Park CG, Cheong C, Brody J, Turley SJ, Lira SA, **Bronte V**, Gordon S, Heeger PS, Merad M, Hutchinson J, Chen SH, Ochando J. DC-SIGN(+) Macrophages control the induction of transplantation tolerance. *Immunity.* 2015 Jun 16;42(6):1143-58. doi:10.1016/j.immuni.2015.05.009. Epub 2015 Jun 9. PMID: 26070485.

Commentato in:

DC-SIGN: The Strange Case of Dr. Jekyll and Mr. Hyde.

Garcia-Vallejo JJ, van Kooyk Y. *Immunity.* 2015 Jun 16;42(6):983-5. doi:

- 10.1016/j.immuni.2015.05.021. PMID: 26084017.
60. Mazzocco M, Martini M, Rosato A, Stefani E, Matucci A, Dalla Santa S, De Sanctis F, Ugel S, Sandri S, Ferrarini G, Cestari T, Ferrari S, Zanovello P, **Bronte V**, Sartoris S. Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma. *Immunology*. 2015 Sep;146(1):33-49. doi:10.1111/imm.12477. Epub 2015 Jun 15-. PMID: 25959091.
61. Cali B, Ceolin S, Ceriani F, Bortolozzi M, Agnellini AH, Zorzi V, Predonzani A, **Bronte V**, Molon B, Mammano F. Critical role of gap junction communication, calcium and nitric oxide signaling in bystander responses to focal photodynamic injury. *Oncotarget*. 2015 Apr 30;6(12):10161-74. doi:10.18632/oncotarget.3553. PMID: 25868859.
62. Arina A, **Bronte V**. Myeloid-derived suppressor cell impact on endogenous and adoptively transferred T cells. *Curr Opin Immunol*. 2015 Apr;33:120-5. doi:10.1016/j.coi.2015.02.006. Epub 2015 Feb 27. PMID: 25728992
63. **Bronte V**, Murray PJ. Understanding local macrophage phenotypes in disease: modulating macrophage function to treat cancer. *Nat Med*. 2015 Feb;21(2):117-9. doi:10.1038/nm.3794. PMID: 25654601.
64. Mazza EMC, Zoso A, Mandruzzato S, **Bronte V**, Serafini P, Inverardi L, Biccato S. Gene expression profiling of human fibrocytic myeloid-derived suppressor cells (f-MDSCs). *Genom Data*. 2014 Oct 31;2:389-92. doi:10.1016/j.gdata.2014.10.018. eCollection 2014 Dec. PMID: 26484135.
65. Damuzzo V, Pinton L, Desantis G, Solito S, Marigo I, **Bronte V**, Mandruzzato S. Complexity and challenges in defining myeloid-derived suppressor cells. *Cytometry B Clin Cytom*. 2014 Nov 26. doi: 10.1002/cytob.21206. online ahead of print. PMID: 25425222.
66. Haverkamp JM, Smith AM, Weinlich R, Dillon CP, Qualls JE, Neale G, Koss B, Kim Y, **Bronte V**, Herold MJ, Green DR, Opferman JT, Murray PJ. Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways. *Immunity*. 2014 Dec 18;41(6):947-59. doi:10.1016/j.immuni.2014.10.020. Epub 2014 Dec 11. PMID: 25500368.
67. **Bronte V**. Tumors STING adaptive antitumor immunity. *Immunity*. 2014 Nov 20; 41(5):679-81. doi:10.1016/J.immuni.2014.11.004. Epub 2014 Nov 20. PMID: 25517609.

Commentato in:

STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.

Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MY, Duggan R, Wang Y, Barber GN, Fitzgerald KA, Alegre ML, Gajewski TF. *Immunity*. 2014 Nov 20;41(5):830-42. doi: 10.1016/j.immuni.2014.10.017. Epub 2014 Nov 5. PMID: 25517615

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.

Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, Li XD, Mauceri H, Beckett M, Darga T, Huang X, Gajewski TF, Chen ZJ, Fu YX, Weichselbaum RR. *Immunity*. 2014 Nov 20;41(5):843-52. doi: 10.1016/j.immuni.2014.10.019. Epub 2014 Nov 6. PMID: 25517616

68. Ricci C, Mota C, Moscato S, D'Alessandro D, Ugel S, Sartoris S, **Bronte V**, Boggi U, Campani D, Funel N, Morini L, Danti S. Interfacing polymeric scaffolds with primary pancreatic ductal adenocarcinoma cells to develop 3D cancer models. *Biomatter*. 2014;4:e955386. doi:10.4161/21592527.2014.955386. PMID: 25482337.
69. Schoenen H, Huber A, Sonda N, Zimmermann S, Jantsch J, Lepenies B, **Bronte V**, Lang R. Differential control of mincle-dependent cord factor recognition and macrophage responses by the transcription factors C/EBP β and HIF1 α . *J Immunol*. 2014 Oct 1;193(7):3664-75. doi:10.4049/jimmunol.1301593. Epub 2014 Aug 25. PMID: 25156364.
70. Zoso A, Mazza EM, Biccato S, Mandruzzato S, **Bronte V**, Serafini P, Iverardi L. Human fibrocytic myeloid-derived suppressor cells expressIDO and promote tolerance via Treg-cell expansion. *Eur J Immunol*. 2014 Nov;44(11):3307-19. doi: 10.1002/eji.201444522. Epub 2014 Oct 18. PMID: 25113564.
71. **Bronte V**. Tumor cells hijack macrophages via lactic acid. *Immunol Cell Biol*. 2014 Sep;92(8):647-9. doi:10.1002/icb.2014.67. Epub 2014 Aug 5. PMID: 25091608.

Commentato in:

Functional polarization of tumour-associated macrophages by tumour-derived lactic acid.

- Colegio OR, Chu NQ, Szabo AL, Chu T, Rhebergen AM, Jairam V, Cyrus N, Brokowski CE, Eisenbarth SC, Phillips GM, Cline GW, Phillips AJ, Medzhitov R. *Nature*. 2014 Sep 25;513(7519):559-63. doi: 10.1038/nature13490. Epub 2014 Jul 13. PMID: 25043024
72. Solito S, Marigo I, Pinton L, Damuzzo V, Mandruzzato S, **Bronte V**. Myeloid-derived suppressor cell heterogeneity in human cancers. *Ann N Y Acad Sci*. 2014 Jun;1319:47-65. doi:10.1111/nyas.12469. PMID: 24965257.
73. Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, **Bronte V**, Chouaib S. PD-L1 is a novel direct target of HIF-1 α , and its blockade under hypoxia enhanced MDSC-mediated T cell activation. *J Exp Med*. 2014 May 5;211(5):781-90. doi:10.1084/jam.20131916. Epub 2014 Apr 28. PMID: 24778419.
74. Ruggero k, Guffanti A, Corradin A, Sharma VK, De Bellis G, Corti G, Grassi A, Zanovello P, **Bronte V**, Ciminale V, D'Agostino DM. Small noncoding RNAs in cells transformed by human T-cell leukemia virus type 1: a role for a tRNA fragment as a primer for reverse transcriptase. *J Virol*. 2014 Apr;88(7):3612-22. doi:10.1128/JVI.02823-13. Epub 2014 Jan 8. PMID: 24403582.
75. Bianchi G, Vuerich M, Pellegatti P, Marimpietri D, Emionite L, Marigo I, **Bronte V**, Di Virgilio F, Pistoia V, Raffaghello L. ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment. *Cell Death Dis*. 2014 Mar 20;5(3):e1135. doi:10.1038/cddis.2014.109. PMID: 24651438.
76. De Sanctis F, Sandri S, Ferrarini G, Pagliarello I, Sartoris S, Ugel S, Marigo I, Molon B, **Bronte V**. The emerging immunological role of post-translational modifications by reactive nitrogen species in cancer microenvironment. *Front Immunol*. 2014 Feb 24;5:69. doi:10.3389/fimmu.2014.00069. eCollection 2014. PMID: 24605112.
77. **Bronte V**, Pittet MJ. The spleen in local and systemic regulation of immunity. *Immunity*. 2013 Nov 14;39(5):806-18. doi:10.1016/j.immuni.2013.10.010. PMID: 24238338.
78. Sonda N, Simonato F, Peranzoni E, Cali B, Bortoluzzi S, Bisognin A, Wang E, Marincola FM, Naldini L, Gentner B, Trautwein C, Sackett SD, Zanovello P, Molon B, **Bronte V**. miR-142-3p prevents macrophage differentiation during cancer-induced myelopoiesis. *Immunity*. 2013 Jun 27;38(6):1236-49.

doi:10.1016/j.immuni.2013.06.004. PMID: 23809164.

79. Hickman HD, Reynoso GV, Ngudiankama BF, Rubin EJ, Magadàn JG, Cush SS, Gibbs J, Molon B, **Bronte V**, Bennink JR, Yewdell JW. Anatomically restricted synergistic antiviral activities of innate and adaptive immune cells in the skin. *Cell Host Microbe*. 2013 Feb 13;13(2):155-68. doi:10.1016/j.chom.2013.01.004. PMID: 23414756.

Commentato in:

Getting in front and behind the enemy lines to counter virus infection.

Lev A, Sigal L. *Cell Host Microbe*. 2013 Feb 13;13(2):121-2. doi:10.1016/j.chom.2013.01.013. PMID: 23414751

80. Schmidt K, Zilio S, Schmollinger JC, **Bronte V**, Blankensteind T, Willimsky G. Differently immunogenic cancers in mice induce immature myeloid cells that suppress CTL in vitro but not in vivo following transfer. *Blood*. 2013 Mar 7;121(10):1740-8. doi:10.1182/blood.-2012-06-436568. Epub 2013 Jan 10. PMID: 23305737.

81. Beghini A, Corlazzoli F, Del Giacco L, Re M, Lazzaroni F, Brioschi M, Valentini G, Ferrazzi F, Ghilardi A, Righi M, Turrini M, Mignardi M, Cesana C, **Bronte V**, Nilsson M, Morra E, Cairoli R. Regeneration-associated WNT signaling is activated in long-term reconstituting AC133bright acute myeloid leukemia cells. *Neoplasia*. 2012 Dec;14(12):1236-48. doi:10.1593/neo.121480. PMID: 23308055.

82. Ugel S, Peranzoni E, Desantis G, Chioda M, Walter S, Weinschenk T, Ochando JC, Cabrelle A, Mandruzzato S, **Bronte V**. Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. *Cell Rep*. 2012 Sep 27;2(3):628-39. doi:10.1016/j.celrep.2012.08.006. Epub 2012 Sep 6. PMID: 22959433.

83. Hammami I, Chen J, **Bronte V**, Decrescenzo G, Jolicoeur M. L-glutamine is a key parameter in the immunosuppression phenomenon. *Biochem Biophys Res Commun*. 2012 Sep 7;425(4):724-9. doi:10.1016/j.bbrc.2012.07.139. Epub 2012 Aug 1. PMID: 22885179.

84. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, Hilf N, Schoor O, Fritsche J, Mahr A, Maurer D, Vass V, Trautwein C, Levandrowski P, Flohr C, Pohla H, Stanczak JJ, **Bronte V**, Mandruzzato S, Bidermann T, Pawelec G,

Derhovanessian E, Yamagishi H, Miki T, Hongo F, Takaha N, Hirawaka K, Tanaka H, Stevanovic S, Frisch J, Mayer-Mokler A, Kirner A, Rammensee HG, Reinhardt C, Singh-Jasuja h. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with no longer patient survival. *Nat Med.* 2012 Aug;18(8):1254-61. doi:10.1038/nm.2883. Epub 2012 Jul 29. PMID: 22842478.

85. Viola A, Sarukhan A, **Bronte V**, Molon B. The pros and cons of chemokines in tumor immunology. *Trends Immunol.* 2012 Oct;33(10):496-504. doi:10.1016/j.it.2012.05.007. Epub 2012 Jun 20. PMID: 22726608.
86. Hammami I, Chen J, Murschel F, **Bronte V**, De Crescenzo G, Jolicoeur M. Immunosuppressive activity enhances central carbon metabolism and bioenergetics in myeloid-derived suppressor cells in vitro models. *BMC Cell Biol.* 2012 Jul 4;13:18. doi:10.1186/1471-2121-13-18. PMID: 22762146.
87. Molon B, Viola A, **Bronte V**. Smoothing T cell roads to the tumor: chemokine post-translational regulation. *Oncoimmunology.* 2012 May 1;1(3):390-392. doi:10.4161/onci.19069. PMID: 22737626.
88. Hammami I, Bertrand M, Chen J, **Bronte V**, De Crescenzo G, Jolicoeur M. Nitric oxide affects immune cells bioenergetics: long-term effects of nitric-oxide derivatives on leukaemic jurkat cell metabolism. *Immunobiology.* 2012 Aug;217(8):808-15. doi:10.1016/j.imbio.2012.05.005. Epub 2012 May 11. PMID: 22656888.
89. Gabrilovich DI, Ostrand-Rosenberg S, **Bronte V**. Coordinated regulation of myeloid cells by tumors. *Nat Rev Immunol.* 2012 Mar 22;12(4):253-68. doi:10.1038/nri3175. PMID: 22437938.
90. Montero AJ, Diaz-Montero CM Kyriakopoulos CE, **Bronte V**, Mandruzzato S. Myeloid-derived suppressor cells in cancer patients: a clinical perspective. *J Immunother.* 2012 Feb-Mar;35(2):107-15. doi: 10.1097/CJI.0b013e318242169f PMID: 22306898.
91. Solito S, Falisi E, Diaz-Montero CM, Doni A, Pinton L, Rosato A, Francescato S, Basso G, Zanovello P, Onicescu G, Garrett-Mayer E, Montero AJ, **Bronte V**, Mandruzzato S. A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. *Blood.* 2011 Aug 25;118(8):2254-65. doi:10.1182/blood-2010-12-325753. Epub 2011 Jul 6. PMID: 21734236.

92. Molon B, Ugel S, Del Pozzo F, Soldani C, Zilio S, Avella D, De Palma A, Mauri P, Monegal A, Rescigno M, Savino B, Colombo P, Jonjic N, Pecanic S, Lazzarotto L, Fruttero R, Gasco A, **Bronte V**, Viola A. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. *J Exp Med*. 2011 Sep 26;208(10):1949-62. doi:10.1084/jem.20101956. Epub 2011 Sep 19. PMID:21930770.
93. Kasic T, Colombo P, Soldani C, Wang CM, Miranda E, Roncalli V, **Bronte V**, Viola A. Modulation of human T cell functions by reactive nitrogen species. *Eur J Immunol*. 2011 Jul;41(7):1843-9. doi:10.1002/eji.201040868. Epub 2011 Jun 7. PMID: 21480210.
94. Ghisi M, Corradin A, basso K, Frasson C, Serafin V, Mukherjee S, Mussolin L, Ruggiero K, Bonanno L, Guffanti A, De Bellis G, Gerosa G, Stellin G, D'Agostino DM, Basso G, **Bronte V**, Indracollo S, Amadori A, Zanovello P. Modulation of micro RNA expression in human T-cell development: targeting of Notch3 by miR-150. *Blood* 2011 Jun 30;117(26):7053-62. doi:10.1182/blood-2010-12-326629. Epub 2011 Jun May 6. PMID: 21551231.
95. Solito S, **Bronte V**, Mandruzzato S. Antigen specificity of immune suppression by myeloid-derived suppressor cells. *J Leukoc Biol*. 2011 Jul;90(1):31-6. doi:10.1189/jlb.0111021. Epub 2011 Apr 12. PMID: 21486906.
96. **Bronte V**. Tolerogenic pDCs: spotlight on Foxo3. *J Clin Invest*. 2011 Apr;121(4):1247-50. doi:10.1172/JCI57190. Epub 2011 Mar 23. PMID: 21436582.
97. Hammami I, Chen J, **Bronte V**, De Crescenzo G, Jolicoeur M. Myeloid-derived suppressor cells exhibit two bioenergetic steady-states in vitro. *J Biotechnol*. 2011 Mar 10;152(1-2):43-8. doi:10.1016/j.jbiotec.2011.01.009. Epub 2011 Jan 22. PMID: 21262283.
98. Chioda M, Peranzoni E, Desantis G, Papalini F, Falisi E, Solito S, Mandruzzato S, **Bronte V**. Myeloid cell diversification and complexity: an old concept with new turns in oncology. *Cancer Metastasis Rev*. 2011 Mar; 30(1):27-43. doi:10.1007/s10555-011-9268-1. PMID: 21267772.
99. Ramonda R, Musacchio E, Campana C, Frigato M, Frallonardo P, Barbieri V, Piccoli A, Valvason C, **Bronte V**, Zanovello P, Punzi L. Immunogenetic aspects of erosive osteoarthritis of the hand in patients from northern Italy. *Scand J Rheumatol*. 2011 Mar;40(2):139-44. doi:10.3109/03009742.2010.507216. Epub

- 2010 Oct 5. PMID: 20919945.
100. Rotondo R, Bertolotto M, Barisione G, Astigiano S, Mandruzzato S, Ottonello L, Dallegri F, **Bronte V**, Ferrini S, Barbieri O. Exocytosis of azurophil and arginase 1-containing granules by activated polymorphonuclear neutrophils is required to inhibit T lymphocyte proliferation. *J LEukoc Biol.* 2011 May;89(5):721-7. doi:10.1189/jlb.1109737. Epub 2011 Feb 17. PMID: 21330347.
 101. Sonda N, Chioda M, Zilio S, Simonato F, **Bronte V**. Transcription factors in myeloid-derived suppressor cell generation. *Curr Opin Immunol.* 2011 Apr;23(2):279-85. doi:10.1016/j.coi.2010.12.006. Epub 2011 Jan 10. PMID: 21227670.
 102. Adeegbe D, Serafini P, **Bronte V**, Zoso A, Ricordi C, Inverardi L. In vivo induction of myeloid suppressor cells and CD4⁺Foxp3⁺ T regulatory cells prolongs skin allograft survival in mice. *Cell Transplant.* 2011;20(6):941-54. doi:10.3727/096368910X540621. Epub 2010 Nov 5. PMID: 21054938.
 103. Fernández A, Mesa C, Marigo I, Dolcetti L, Clavell M, Oliver L, Fernández LE, **Bronte V**. Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant. *J Immunol.* 2011 Jan 1;186(1):264-74. doi:10.4049/jimmunol.1001465. Epub 2010 Dec 6. PMID: 21135171.
 104. Dolcetti L, Peranzoni E, **Bronte V**. Measurement of myeloid cell immune suppressive activity. *Curr Protoc Immunol.* 2010 Nov;Chapter 14:Unit 14.17. doi:10.1002/0471142735.im1417s91. PMID: 21053303.
 105. Di Camillo B, Sanavia T, Iori E, **Bronte V**, Roncaglia E, Maran A, Avogaro A, Toffolo G, Cobelli C. The transcriptional response in human umbilical vein endothelial cells exposed to insulin: a dynamic gene expression approach. *PLoS One.* 2010 Dec 22;5(12):e14390. doi:10.1371/journal.pone.0014390. PMID: 21203503.
 106. Martini M, Testi MG, Pasetto M, Picchio MC, Innamorati G, Mazzocco M, Ugel S, Cingarlini S, **Bronte V**, Zanovello P, Krampera M, Mosna F, Cestari T, Riviera AP, Brutti N, Barbieri O, Matera L, Tridente G, Colombatti M, Sartoris S. IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. *Vaccine.* 2010 Apr 30;28(20):3548-57. doi:10.1016/j.vaccine.2010.03.007. Epub 2010 Mar 19. PMID: 20304037.
 107. Ruggiero K, Corradin A, Zanovello P, Amadori A, **Bronte V**, Ciminale V,

- D'Agostino DM. Role of microRNAs in HTLV-1 infection and transformation. *Mol Aspects Med.* 2010 Oct;31(5):367-85. doi:10.1016/j.mam.2010.05.001. Epub 2010 Jun 17. PMID: 20600265.
108. Marigo I, Bosio E, Solito S, Mesa C, Fernández A, Dolcetti L, Ugel S, Sonda N, Biciato S, Falisi E, Calabrese F, Basso G, Zanovello P, Cozzi E, Mandruzzato S, **Bronte V**. Tumor-induced tolerance and immune suppression depend on C/EBP β transcription factor. *Immunity.* 2010 Jun 25;32(6):790-802. doi:10.1016/j.immuni.2010.05.010. Epub 2010 Jun 3. PMID: 20605485.
109. Grohmann U, **Bronte V**. Control of immune response by amino acid metabolism. *Immunol Rev.* 2010 Jul;236:243-64. doi:10.1111/j.1600-065X.2010.00915.x. PMID: 20636821.
110. Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, Mandruzzato S, **Bronte V**. Myeloid-derived suppressor cell heterogeneity and subset definition. *Curr Opin Immunol.* 2010 Apr;22(2):238-44. doi:10.1016/j.coi.2010.01.021. Epub 2010 Feb 17. PMID: 20171075.
111. Ugel S, Scarselli E, Iezzi M, Mennuni C, Pannellini T, Calvaruso F, Cipriani B, De Palma R, Ricci-Vitiani L, Peranzoni E, Musiani P, Zanovello P, **Bronte V**. Autoimmune B cell lymphopenia following successful adoptive therapy with telomerase-specific T lymphocytes. *Blood.* 2010 Feb 18;115(7):1374-84. doi:10.1182/blood-2009-07-233270. Epub 2009 Nov 10. PMID: 19903903.
- Commentato in:
- Targeting telomerase: T-cell friendly fire.**
- Calado RT. *Blood.* 2010 Feb 18;115(7):1316. doi: 10.1182/blood-2009-12-254961. PMID: 20167708
112. Dolcetti L, Peranzoni E, Ugel S, Marigo I, Fernandez Gomez A, Mesa C, Geilich M, Winkels G, Traggiai E, Casati A, Grassi F, **Bronte V**. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subset is determined by GM-CSF. Frontline paper. *Eur J Immunol.* 2010 Jan;40(1):22-35. doi:10.1002/eji.200939903. PMID: 19941314.
113. Ugel S, Zoso A, De Santo C, Li Y, Marigo I, Zanovello P, Scarselli E, Cipriani B, Schneck JP, Oelke M, **Bronte V**. In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer. *Cancer Res.* 2009 Dec 15;69(24):9376-84. doi:10.1158/0008-5472.CAN-09-0400. PMID: 19934317.

114. **Bronte V**. Myeloid-derived suppressor cells in inflammation: uncovering cell subsets with enhanced immunosuppressive functions. *Eur J Immunol*. 2009 Oct; 39(10):2670-2 doi: 10.1002/eji.200939892. PMID: 19757440.
- Commentato in:
- Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development.**
- Greifenberg V, Ribechini E, Rössner S, Lutz MB. *Eur J Immunol*. 2009 Oct;39(10):2865-76. doi: 10.1002/eji.200939486. PMID: 19637228
115. Ugel S, Delpozzi F, Desantis G, Papalini F, Simonato F, Sonda N, Zilio S, **Bronte V**. Therapeutic targeting of myeloid-derived suppressor cells. *Curr Opin Pharmacol*. 2009 Aug;9(4):470-81 doi:10.1016/j.coph.2009.06.014. Epub 2009 Jul 16. PMID: 19616475.
116. Persano L, Moserle L, Esposito G, **Bronte V**, Barbieri V, Lafrate M, Gardiman MP, Larghero P, Pfeffer U, Naschberger E, Stürzl M, Indraccolo S, Amadori A. Interferon-alpha counteracts the angiogenic switch and reduces tumor cell proliferation in a spontaneous model of prostatic cancer. *Carcinogenesis*. 2009 May;30(5):851-60. doi:10.1093/carcin7b9p052. Epub 2009 Feb 23. PMID: 19237608.
117. **Bronte V**, Mocellin S. Suppressive influences in the immune response to cancer. *J Immunother*. 2009 Jan;32(1):1-11. doi:10.1097/CJI.0b013e3181837276. PMID: 19307988.
118. Mandruzzato S, Solito S, Falisi E, Francescato S, Chiarion-Sileni V, Mocellin S, Zanon A, Rossi CR, Nitti D, **Bronte V**, Zanovello P. IL4Ralpha+myeloid-derived suppressor cell expansion in cancer patients. *J Immunol*. 2009 May 15;182(10):6562-8. doi:10.4049/jimmunol.0803831. PMID: 19414811.
119. Tosello V, Zamarchi R, Merlo A, Gorza M, Piovan E, Mandruzzato S, **Bronte V**, Wang X, Ferrone S, Amadori A, Zanovello P. Differential expression of constitutive and inducible proteasome subunits in human monocyte-derived DC differentiated in the presence of IFN-alpha or IL-4. *Eur J Immunol*. 2009 Jan;39(1):56-66. doi:10.1002/eji.200738098. PMID: 19065646.
120. Mennuni C, Ugel S, Mori F, Cipriani B, Iezzi M, Pannellini M, Lazzaro D, Ciliberto G, La Monica N, Zanovello P, **Bronte V**, Scarselli E. Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer. *Cancer Res*. 2008 Dec 1;68(23):9865-74.

doi:10.1158/0008-5472.CAN-08-1603. PMID: 19047176.

121. **Bronte V**. Th17 and cancer: friends or foes? *Blood*. 2008 Jul 15;112(2):214. doi:10.1182/blood-2008-04-149260. PMID: 18606882.

Commentato in:

Tumor-specific Th17-polarized cells eradicate large established melanoma.

Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K, Gattinoni L, Wrzesinski C, Hinrichs CS, Kerstann KW, Feigenbaum L, Chan CC, Restifo NP. *Blood*. 2008 Jul 15;112(2):362-73. doi: 10.1182/blood-2007-11-120998. Epub 2008 Mar 19. PMID: 18354038

122. Dolcetti L, Marigo I, Mantelli B, Peranzoni E, Zanovello P, **Bronte V**. Myeloid-derived suppressor cell role in tumor-related inflammation. *Cancer Lett*. 2008 Aug 28;267(2):216-25 doi:10.1016/j.canlet.2008.03.012 Epub 2008 Apr 22. PMID: 18433992.

123. Marigo I, Dolcetti L, Serafini P, Zanovello P, **Bronte V**. Tumor-induced tolerance and immune suppression by myeloid-derived suppressor cells. *Immunol Rev*. 2008 Apr;222:162-79. doi:10.1111/j.1600-065X.2008.00602.x. PMID: 18364001.

124. Peranzoni E, Marigo I, Dolcetti L, Ugel S, Sonda N, Taschin E, Mantelli B, **Bronte V**, Zanovello P. Role of arginine metabolism in immunity and immunopathology. *Immunobiology*. 2007;212(9-10):795-812. doi:10.1016/j.imbio.2007.09.008. Epub 2007 Nov 14. PMID: 18086380.

125. Viola A, **Bronte V**. Metabolic mechanisms of cancer-induced inhibition of immune responses. *Semin Cancer Biol*. 2017 Aug;17(4):309-16. doi:10.1016/j.semcancer.2007.06.005. Epub 2007 Jun 23. PMID: 17651958.

126. Sica A, **Bronte V**. Altered macrophage differentiation and immune dysfunctions during tumor development. *J Clin Invest*. 2007 May;117(5):1155-6. doi:10.1172/JCI31422. PMID: 17476345.

127. Gabrilovich DI, **Bronte V**, Chen SH, Colombo MP, Ochoa A, Ostrand-Rosenberg S, Schreiber H. The terminology issue for myeloid-derived suppressor cells. *Cancer Res*. 2007 Jan 1;67(1):425; author reply 426. doi:10.1158/0008-5472.CAN-06-3037. PMID: 17210725.

Commentato in:

Re: The terminology issue for myeloid-derived suppressor cells.

- Kristal G, Sly L, Antignano F, Ho V, Ruschmann J, Hamilton M. *Cancer Res.* 2007 Apr 15;67(8):3986. doi: 10.1158/0008-5472.CAN-07-0211. PMID: 17440115.
128. Mocellin S, **Bronte V**, Nitti D. Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities. *Med Res Rev.* 2007 May;27(3):317-52. doi:10.1002/med.20092. PMID: 16991100.
129. Serafini P, Meckel K, Kelso M, Noonan KA, Califano J, Koch W, Dolcetti L, **Bronte V**, Borrello I. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. *J Exp Med.* 2006 Nov 27;203(12):2691-702. doi:10.1084/jem.0061104. Epub 2006 Nov 13. PMID: 17101732.
130. Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP, Basso G, Brombacher F, Borrello I, Zanovello P, Biccato S, **Bronte V**. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. *J Clin Invest.* 2006 Oct;116(10):2777-90. doi:10.1172/JCI28828. PMID: 17016559.
- Commentato in:
- Myeloid suppressor cells regulate the adaptive immune response to cancer.**
- Frey AB. *J Clin Invest.* 2006 Oct;116(10):2587-90. doi: 10.1172/JCI29906. PMID: 17016554.
131. **Bronte V**, Cingarlini S, Marigo I, De Santo C, Gallina G, Dolcetti L, Ugel S, Peranzoni E, Mandruzzato S, Zanovello P. Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: a novel target for therapeutic intervention. *Immunol Invest.* 2006;35(3-4):327-57. doi:10.1080/08820130600754994. PMID: 16916757.
132. Orabona C, Puccetti P, Vacca C, Biccato S, Luchini A, Fallarino F, Bianchi R, Perruccio K, Velardi A, **Bronte V**, Fioretti MC, Grohmann U. Towards the identification of a tolerogenic signature in IDO-competent dendritic cells. DAP12 and IRF-8 regulate tryptophan catabolism. *Blood.* 2006 Apr 1;107(7):2846-54. doi:10.1182/blood-2005-10-4077. Epub 2005 Dec 8. PMID: 16339401.
133. Biswas Sk, Gangi L, Paul S, Schioppa T, Saccani A, Sironi M, Bottazzi B, Doni A, **Bronte V**, Pasqualini F, Vago L, Nebuloni M, Mantovani A, Sica A. A distinct and unique transcriptional program expressed by tumor-associated

macrophages: defective NF- κ B and enhanced IRF-3/STAT1 activation. *Blood*. 2006 Mar 1;107(5):2112-22. doi:10.1182/blood-2005-01-0428. Epub 2005 Nov 3. PMID: 16269622.

134. Serafini P, Borrello I, **Bronte V**. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. *Semin Cancer Biol*. 2006 Feb;16(1):53-65. doi:10.1016/j.semcancer.2005.07.005. Epub 2005 Sep 15. PMID: 16168663.
135. Mocellin S, Mandruzzato S, Zanovello P, **Bronte V**. Cancer rejection by the immune system: forcing the check-points of tumor immune escape. *Drug Discovery Today: disease mechanisms*; 2:191-197, 2005. doi:10.1016/j.ddmec.2005.05.016
136. **Bronte V**, Zanovello P. Regulation of immune responses by L-arginine metabolism. *Nat Rev Immunol*. 2005 Aug;5(8):641-54. doi:10.1038/nri1668. PMID: 16056256.
137. Avogadri F, Martinoli C, Petrovska L, Chiodoni C, Transidico P, **Bronte V**, Colombo MP, Dougan G, Rescigno M. Cancer immunotherapy based on killing of Salmonella-infected tumor cells. *Cancer Res*. 2005 May 1;65(9):3920-7. doi:10.1158/0008-5472.CAN-04-3002. PMID: 15867392.
138. **Bronte V**, Kasic T, Gri G, Gallana K, Borsellino G, Marigo I, Battistini L, Iafrate M, Prayer-Galetti T, Pagano F, Viola A. Boosting anti-tumor responses of T lymphocytes infiltrating human prostate cancers. *J Exp Med*. 2005 Apr 18;201(8):1257-68. doi:10.1084/jem.20042028. Epub 2005 Apr 11. PMID: 15824085.
139. De Santo C, Serafini P, Marigo I, Dolcetti L, Bolla M, Del Soldato P, Melani C, Guiducci C, Colombo MP, Iezzi M, Musiani P, Zanovello P, **Bronte V**. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. *Proc Natl Acad Sci U S A*. 2005 Mar 15;102(11):4185-90. doi:10.1073/pnas.0409783102. Epub 2005 Mar 7. PMID: 15753302.
140. Mocellin S, Mandruzzato S, **Bronte V**, Marincola F. Cancer Vaccines: pessimism in check. *Nat Med*. 2004 Dec;10(12):1278-9; author reply 1279-80. doi:10.1038/nm1204-1278. PMID: 15580242.

Commentato in:

Cancer immunotherapy: moving beyond current vaccines.

- Rosenberg SA, Yang JC, Restifo NP. Nat Med. 2004 Sep;10(9):909-15. doi: 10.1038/nm1100. PMID: 15340416
141. Mocellin S, Madruzzo S **Bronte V**, Lise M, Nitti D. Part 1: vaccines for solid tumors. Lancet Oncol. 2004 Nov;5(11):681-9. doi:10.1016/S1470-2045(04)01610-9. PMID: 15522656.
- Commentato in:
- Use of standard criteria for assessment of cancer vaccines.**
- Restifo NP, Rosenberg SA. Lancet Oncol. 2005 Jan;6(1):3-4. doi: 10.1016/S1470-2045(04)01693-6. PMID: 15629270
142. De Palma R, Marigo I, Del Galdo F, De Santo C, Serafini P, Cingarlini S, Tüting T, Lenz J, Basso G, Zanovello P, **Bronte V**. Therapeutic effectiveness of recombinant cancer vaccines is associated with a prevalent TCR- α usage by melanoma-specific CD8+ T lymphocytes. Cancer Res. 2004 Nov 1;64(21):8086-76. doi:10.1158/0008-5472.CAN-04-0067. PMID: 15520218.
143. Serafini P, Carbley R, Noonan KA, Tan G, **Bronte V**, Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune system through the recruitment of myeloid suppressor cells. Cancer Res. 2004 Sep 1;64(17):6337-43. doi:10.1158/0008-5472.CAN-04-0757. PMID: 15342423.
144. Sfondrini L, Besusso D, **Bronte V**, Macino B, Rossini A, Colombo MP, Menard S, Balsari A. CpG-Oligodeoxynucleotides activate tyrosinase-related protein 2-specific T lymphocytes but do not lead to a protective tumor-specific memory response. Cancer Immunother. 2004 Aug;53(8):697-704. doi:10.1007/s00262-004-0516-x. Epub 2004 Mar 18. PMID: 15034674.
145. **Bronte V**, Cingarlini S, Apolloni E, Sefaini P, Marigo I, De Santo C, Macino B, Marin O, Zanovello P. Effective genetic vaccination with a widely shared endogenous retroviral tumor antigen requires CD40 stimulation during tumor rejection phase. J Immunol. 2003 Dec 15;171(12):6396-405. doi:10.4049/jimmunol.171.12.6396. PMID: 14662838.
146. Serafini P, De Santo C, Marigo I, Cingarlini S, Dolcetti L, Gallina G, Zanovello P, **Bronte V**. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother. 2004 Feb;53(2):64-75. doi:10.1007/s00262-003-0443-2 Epub 2003 Oct 30. PMID: 14593498.
147. Cozzi E, Cadrobbi R, Baldan N, Dedja A, Calabrese F, Castagnaro M, Fante F,

- iacopetti I, Ravarotto L, Carraro P, **Bronte V**, De Santo C, Busetto R, Plebani M, Cancellotti FM, Rigotti P, Thiene G, Ancona E. Methotrexate for immunosuppression in life-supporting pig-to-cynomolgus monkey renal xenotransplantation. *Xenotransplantation*. 2003 Nov;10(6):287-95. doi:10.1034/j.1399-3089.2003.00060.x. PMID: 14708527.
148. **Bronte V**, Serafini P, Mazzoni A, Segal DM, Zanovello P. L-arginine metabolism in myeloid cells controls T lymphocyte functions. *Trends Immunol*. 2003 Jun;24(6):302-6. doi:10.1016/s1471-4906(03)00132-7. PMID: 12810105.
149. **Bronte V**, Serafini P, Marigo I, De Santo C, Tosello V, Mazzoni A, Segal DM, Staib C, Lowel M, Sutter G, Colombo MP, Zanovello P. IL-4 induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. *J Immunol*. 2003 Jan 1; 170(1):270-8 doi:10.4049/jimmunol.170.1.270. PMID: 12496409.
150. Mazzoni A, **Bronte V**, Visintin A, Spitzer JH, Apolloni E, Serafini P, Zanovello P, Segal DM. Myeloid suppressor lines inhibit T cell responses by a nitric oxide dependent mechanism. *J Immunol*. 2002 Jan 15;168(2):689-95. doi:10.4049/jimmunol.168.2.689. PMID: 11777962.
151. Milan G, Apolloni A, **Bronte V**, Dalla Santa S, Macino B, Mandruzzato S, Rosato A, Quinteri L, Serafini P, Zoso A, Zanovello P. Antitumors DNA vaccines. *J Immunol. Immunopharmacol.*, 21:86-93, 2001.
152. **Bronte V**, Serafini P, Apolloni E, Zanovello P. Tumor-induced dysfunctions caused by myeloid suppressor cells. *J Immunother*. 2001 Nov-Dec;24(6):431-46. doi:10.1097/00002371-200111000-00001. PMID: 11759067.
153. **Bronte V**. Genetic vaccination for the active immunotherapy of cancer. *Curr Gene Ther*. 2001 May;1(1):53-100. doi:10.2174/1566523013348931. PMID: 12109138.
154. Mendiratta KS, Thai G, Eslahi NK, Thull N, Matar M, **Bronte V**, Pericle F. Therapeutic tumor immunity induced by pole-immunization with melanoma antigens gp100 and TRP-2. *Cancer Res*. 2001 Feb 1;61(3):859-63. PMID: 11221870.
155. Bocchia M, **Bronte V**, Colombo MP, De Vincentiis A, Di Nicola M, Forni G, Lanata L, Lemoli RM, Massaia M, Rondinelli D, Zanon P, Tura S. Antitumor vaccination: where we stand. *Haematologica*. 2000 Nov;85(11):1172-206. PMID: 11074658.
156. Apolloni E, **Bronte V**, Mazzoni A, Serafini P, Cabrelle A, Segal DM, Young HO,

- Zanovello P. Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes. *J Immunol.* 2000 Dec 15;165(12):6723-30. doi:10.4049/jimmunol.165.12.6723. PMID: 11120790.
157. **Bronte V**, Apolloni E, Cabrelle A, Ronca R, Serafini P, Zanovello P, Restifo NP, Zanovello P. Identification of a CD11b+/Gr-1/CD31+ myeloid progenitor capable of activating or suppressing CD8+ T cells. *Blood.* 2000 Dec 1;96(12):3838-46. PMID: 11090068.
158. **Bronte V**, Apolloni E, Ronca R, Zamboni P, Overwijk WW, Surman DR, Restifo NP, Zanovello P. Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. *Cancer Res.* 2000 Jan 15;60:253-8. PMID: 10667570.
159. Lollini PL, **Bronte V**. The immunotherapy of cancer: understanding the mechanisms through animal models. *Minerva Biotechn.*, 11:283-294, 1999.
160. Kaufman HL, Rao JB, Irvine KR, **Bronte V**, Rosenberg SA, Restifo NP. Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model. *J Immunother.* 1999 Nov;22(6):489-96. doi:10.1097/00002371-199911000-00003. PMID: 10570747.
161. **Bronte V**, Chappell DB, Apolloni E, Cabrelle A, Wang M, Hwu P, Restifo NP. Unopposed production of GM-CSF by tumors inhibits CD8+ T cell responses by dysregulating antigen presenting cell maturation. *J Immunol.* 1999 May 15;162(10):5728-37. PMID: 10229805.
162. **Bronte V**, Wang M, Overwijk WW, Surman DR, Pericle F, Rosenberg SA, Restifo NP. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. *J Immunol.* 1998 Nov 15; 161(10):5313-20. PMID: 9820504.
163. Pericle F, Kirken RA, **Bronte V**, Sconocchia G, DaSilva L, Segal DM. Immunocompromised tumor-bearing mice show a selective loss of STAT5a/b expression in T and B lymphocytes. *J Immunol.* 1997 Sep 15;159(6):2580-5. PMID: 9300676.
164. **Bronte V**, Carroll MW, Goletz TJ, Wang W, Overwijk WW, Marincola F, Rosenberg SA, Moss B, Restifo NP. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. *Proc Natl Acad Sci U S A.* 1997 Apr 1;94(7):3183-8. doi:10.1073/pnas.94.7.3183. PMID: 9096367.

165. Chamberlain RS, Carroll MW, **Bronte V**, Hwu P, Warren S, Yang JC, Nishimura M, Moss B, Rosenberg SA, Restifo NP. Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. *Cancer res.* 1996 Jun 15; 56(12):2832-6. PMID: 8665522.
166. Rao JB, Chamberlain RS, **Bronte V**, Carroll MW, Irvine K, Moss B, Rosenberg SA, Restifo NP. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. *J Immunol.* 1996 May 1;156(9):3357-65. PMID: 8617961.
167. **Bronte V**, Macino B, Zambon A, Rosato A, Mandruzzato S, Zanovello P, Collavo D. Protein tyrosine kinases and phosphatases control apoptosis induced by extracellular adenosine 5'-triphosphate. *Biochem Biophys Res Commun.* 1996 Jan 5;218(1):344-51. doi:10.1006/bbrc.1996.0060. PMID: 8573158.
168. Chen PW, Wang M, **Bronte V**, Zhai Y, Rosenberg SA, Restifo NP. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. *J Immunol.* 1996 Jan 1; 156(1):224-31. PMID: 8598466.
169. Rosato A, Zambon A, Macino B, Mandruzzato S, **Bronte V**, Milan G, Zanovello P, Collavo D. Anti-L-selectin monoclonal antibody treatment in mice enhances tumor growth by preventing CTL sensitization in peripheral lymph nodes draining the tumor area. *Int J Cancer.* 1996 Mar 15;65(6):847-51. doi:10.1002(SICI)1097-0215(19960315)65:6<847:AID-IJC23>3.0.CO;2-#. PMID: 8631602.
170. **Bronte V**. Molecular genetics of cancer. Gene therapy and other novel therapeutic approaches. *Cancer.* 1995 Nov 15; 76(10):1878-81. doi: 10.1002/1097-0142(19951115)76:10<1878:aid-cnrcr2820761032>3.0.co;2-7. PMID: 8625063.
171. Rosato A, Mandruzzato S, **Bronte V**, Zambon A, Macino B, Calderazzo F, Zanovello P, Collavo D. Role of anti-LFA-1 and anti-ICAM-1 combined Mab treatment in the rejection of tumors induced by Moloney murine sarcoma virus (M-MSV). *Int J Cancer.* 1995 May 4;61(3):355-62. doi:10.1002/ijc.2910610314. PMID: 7729948.
172. Di Virgilio F, Zanovello P, Zambon A, **Bronte V**, Pizzo P, Murgia M. Cell membrane receptors for extracellular ATP: a new family of apoptosis-signalling molecules. *Fund Clin Immunol.* 1995; 3:80-81.
173. Wang M, Chen PW, **Bronte V**, Zhai Y, Rosenberg SA, Restifo NP. Anti-tumor

- activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor antigen. *J Immunother Emphasis Tumor Immunol.* 1995 Oct;18(3):139-46 doi:10.1097/00002371-199510000-00001. PMID: 8770769.
174. **Bronte V**, Tsung K, Rao JB, Chen PW, Wang M, Rosenberg SA, Restifo NP. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. *J Immunol.* 1995 May 15;154(10):5282-92. PMID: 7730632.
175. Wang M, **Bronte V**, Chen PW, Gritz L, Panicali D, Rosenberg SA, Restifo NP. Active Immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. *J Immunol.* 1995 May 15;154(9):4685-92. PMID: 7722321.
176. Rosato A, Zambon A, Mandruzzato S, **Bronte V**, Macino B, Calderazzo F, Collavo D, Zanovello P. Inhibition of protein tyrosine phosphorylation prevents T-cell mediated cytotoxicity. *Cell Immunol.* 1994 Dec;159(2):294-305. doi:10.1006/cimm.1994.1315. PMID: 7994761.
177. Zambon A, **Bronte V**, Di Virgilio F, Hanau S, Steinberg TH, Collavo D, Zanovello P. Role of extracellular ATP in cell-mediated cytotoxicity: a study with ATP-sensitive and ATP-resistant macrophages. *Cell Immunol.* 1994 Jul;156(2):458-67. doi:10.1006/cimm.1994.1190. PMID: 8025958.
178. Mandruzzato S, Rosato A, **Bronte V**, Zanovello P, Amboldi N, Ballinari D, Collavo D. Adoptive transfer of lymphokine-activated killer cells loaded with 4'-deoxy-4'-iododoxorubicin: therapeutic effect in mice bearing lung metastases. *Cancer Res.* 1994 Feb 15;54(4):1016-20. PMID: 8313356.
179. **Bronte V**, Zanovello P, Rosato A, Zambon A, Mandruzzato S, Pizzo P, Di Virgilio F, Collavo D. Synergistic effect of extracellular adenosine 5' - triphosphate and tumor necrosis factor on DNA degradation. *Cell Immunol.* 1993 Nov; 152(1):110-9. doi: 10.1006/cimm.1993.1271. PMID: 8242754.
180. Rosato A, **Bronte V**, Mandruzzato S, Zambon A, Calderazzo F, Biasi G, Zanovello P, Collavo D. Role of adhesion molecules in the immune reaction to M-MSV-induced tumors. *Int J Cancer Suppl.* 1992;7:24. PMID: 1385341.
181. Mandruzzato S, Rosato A, **Bronte V**, Pollis F, Zambon A, Zanovello P, Collavo D. Therapeutical effect of 4'-deoxy-4'-iododoxorubicin-loaded LAK cells in mice bearing lung metastases. *Pharmacol Res.* 1992 Sep;26 Suppl 2:124-5. doi:10.1016/1043-6618(92)90628-o. PMID: 1409274.

182. Pollis F, **Bronte V**, Mandruzzato S, Rosato A, Zambon A, Zanovello P, Zambello R, Callegaro L, Collavo D. Inhibition of CTL-line lysis after gangliosides treatment. *Pharmacol Res.* 1992 Sep; 26Suppl 2:190-1. doi:10.1016/1043-6618(92)90659-y. PMID: 1409305.
183. Pollis F, Rosato A, **Bronte V**, Mandruzzato S, Zambon A, Zambello R, Pizzo P, Zanovello P. Interaction of large granular lymphocytes with susceptible target does not induce second messenger and cytolytic granule exocytosis. *Leukemia.* 1992; 6 Suppl 3:92S-93S. PMID: 1602835.
184. Rosato A, **Bronte V**, Pollis F, Mandruzzato S, Zambon A, Zanovello P, Collavo D. The in vivo role of leukocyte function-associated antigen-1 (LFA-1) in cytotoxic cell activity against tumors induced by the retroviral complex M-MSV/M-MuLV. *Leukemia.* 1992; 6 Suppl 3:166S-167S. PMID: 1602816.
185. Zanovello P, Rosato A, **Bronte V**, Mandruzzato S, Cerundolo V, Collavo D. Anti-tumor efficacy of lymphokine-activated killer cells loaded with ricin against experimentally induced lung metastases. *Cancer Immunol Immunother.* 1992;35(1):27-32. doi:10.1007/BF01741051. PMID: 1611620.
186. Pizzo P, Murgia M, Zambon A, Zanovello P, **Bronte V**, Di Virgilio F. Role of P2z purinergic receptors in ATP-mediated killing of TNF-sensitive and TNF-resistant L929 fibroblasts. *J Immunol.* 1992 Nov 15;149(10):3372-8. PMID: 1431111.
187. Pizzo P, Zanovello P, **Bronte V**, Di Virgilio F. Extracellular ATP causes lysis of mouse thymocytes and activates a plasma membrane ion channel. *Biochem J.* 1991 Feb 15;274(Pt 1)(Pt1):139-44. doi:10.1042/bj2740139. PMID: 1705798.
188. Zanovello P, Vallerani E, **Bronte V**, Rosato A, Chieco-Bianchi L, Collavo D. Tolerance induction in adult mice intrathecally injected with moloney murine leukemia virus and treated with cyclophosphamide. *J Immunol. Research.* 2:151-156, 1990.
189. Zanovello P, **Bronte V**, Rosato A, Pizzo P, Di Virgilio F. Responses of mouse lymphocytes to extracellular ATP. II. Extracellular ATP causes cell type-dependent lysis and DNA fragmentation. *J Immunol.* 1990 Sep 1;145(5):1545-50. PMID: 2384670.
190. Di Virgilio F, Pizzo P, Zanovello P, **Bronte V**, Collavo D. Extracellular ATP as a possible mediator of cytotoxicity. *Immunol Today.* 1990 Aug;11(8):247-7. doi:10.1016/0167-5699(90)90111-I. PMID: 2206271.
191. Di Virgilio F, **Bronte V**, Collavo D, Zanovello P. Responses of mouse lymphocytes

- to extracellular adenosine 5' - triphosphate (ATP). *J Immunol.* 1989 Sep 15; 143(6):1955-60. PMID: 2789252.
192. Zanollo P, Cerundolo V, **Bronte V**, Giunta M, Panozzo M, Biasi G, Collavo D. Resistance of lymphokine-activated T lymphocytes to cell-mediated cytotoxicity. *Cell Immunol.* 1989 Sep;122(2):450-60. doi:10.1016/0008-8749(89)90091-9. PMID: 2788517.
193. Zanollo P, Rosato A, **Bronte V**, Cerundolo V, Treves S, Di Virgilio F, Pozzan T, Biasi G, Collavo D. Interaction of lymphokine-activated killer cells with susceptible targets does not induce second messenger generation and cytolytic granule exocytosis. *J Exp Med.* 1989 Sep 1;170(3):665-77. doi:10.1084/jem.170.3.665. PMID: 2769181.

LIBRI, CAPITOLI E MONOGRAFIE

1. Barouni RZ, Musiu C, **Bronte V**, Ugel S, Canè S. Phenotypical characterization and isolation of tumor-derived mouse MDSCs. *Methods Mol Biol.* 2021;2236:29-42. doi:10.1007/978-1-0716-1060-2_4. PMID: 33237538.
2. Canè S, **Bronte V**. Detection and functional evaluation of arginase-1 isolated from human PMNs and Murine MDSC. *Methods Enzymol.*, 2020;632:193-213. doi:10.1016/bs.mie.2019.07.022. Epub 2019 Aug 12. PMID: 32000896
3. De Sanctis F, **Bronte V**, Ugel S. Tumor-induced myeloid-derived suppressor cells. *Microbiol Spectr.* 2016. Jun4(3). doi:10.1128/microbiolspec.MCHD-0016-2015. PMID: 27337449
4. Serafini P, **Bronte V**. Myeloid-derived suppressor cells in tumor-induced T cell suppression and tolerance. In: Gabrilovich DI; Hurwitz AA. *Tumor-induced immune suppression: mechanism and therapeutic reversal.* 2014. Springer.
5. Sasso MS, **Bronte V**, Marigo I. Cancer immune modulation and immunosuppressive cells: current and future therapeutic approaches. In: Alonso MJ and Garcia-Fuentes M. *Nano-oncologicals: new targeting and delivery approaches.* *Advances in delivery science and technology.* 2014. Springer.

6. Chioda M, Marigo I, Mandruzzato S, Mocellin S, **Bronte V**. Arginase nitric oxide synthase and novel inhibitors of L-arginine metabolism in immune modulation in "Cancer immunotherapy: immune suppression and tumor growth". Edited by Prendergast GC and Jafee EM. 2013.
7. Baadn W, **Bronte V**. Myeloid derived suppressor cells in cancer. In "Innate and adaptive immune regulation and cancer immunotherapy", edited by Wang RF. 2011. Springer.
8. Serafini P, **Bronte V**. Myeloid-derived suppressor cells in cancer in "Tumor-induced immune suppression. Mechanisms and therapeutic reversal", edited by Gabrilovich DI and Hurwitz AA. 2008. Springer.
9. Mandruzzato S, Mocellin S, **Bronte V**. "Arginase, nitric oxide synthase, and novel inhibitors of L-arginine metabolism" in "Cancer Immunotherapy", edited by Prendergast GC and Jafee EM. 2007. Academic Press.
10. Mocellin S, **Bronte V**. Suppressive influences in the immune response to cancer, in "Principles and practice of oncology". Focus, Vol. 1, No. 4. Lippincott Williams & Wilkins. 2007.
11. Macino B, Tosello V, Mandruzzato S, **Bronte V**, Rosato A, Cingarlini S, Dalla Santa S, De Santo C, Marigo I, Rosi E, Zoso A, Gorza M, Zanovello P. Valutazione citometrica della risposta immunitaria mediata dai linfociti T citotossici. Uso della tecnologia dei tetrameri. "Quaderni di citometria pratica". A cura di Basso G. Vol. 2. 2003.
12. Di Virgilio F, Ferrari D, Munerati M, Falzoni S, Villalba M, **Bronte V**, Zambon A, Zanovello P, Steinberg TH. The P2z receptor and its regulation of macrophage function. In: adenosine and adenine nucleotides, A. Pelleg Ed. Kluwer press. 1994.
13. Macino B, Zambon A, **Bronte V**, Rosato A, Mandruzzato S, Calderazzo F, Mezzalana S, Zanovello P, Collavo D. Studio dei segnali intracellulari coinvolti nell'induzione della morte cellulare programmata. In: "Immunopatologia 1994", 647-650. Monduzzi Ed. 1993.
14. Zanovello P, Rosato A, **Bronte V**, Cerundolo V, Collavo D. Adoptive immunotherapy of experimental tumors using cytotoxic lymphocytes to carry and deliver toxins. In: "Immunology and biotechnology". Ann. Ist. Sup. Sanità. Colizzi V, Marini S, Pugliese O, Eds 27, 91-95. 1991.

15. Collavo D, Zanovello P, Rosato A, **Bronte V**, Facchinetti A, Biasi G. La risposta immunologica verso antigeni tumorali specifici. In: "I modificatori della risposta biologica", 15-20. 1991.
16. Zanovello P, Vellerani E, **Bronte V**, Rosato A, Collavo D, Chieco-Bianchi L. Tolerance induction and leukemia development in M-MuLV intrathymically injected adult mice treated with cyclophosphamide. Arch. Geschwulstforsch. 60, 423-428. 1990.
17. Collavo D, Zanovello P, **Bronte V**, Rosato A, Biasi G. Meccanismi molecolari della lisi mediata dei linfociti citotossici. Aggiornamento del medico, 14, 720-726. 1990.

CONFERENZE E SEMINARI SU INVITO E PRESENTAZIONI

1. **Bronte V**. Member of international secretary - CICON21 6th International Cancer Immunotherapy Conference. 22/09 al 25/09 - 2021, Milano, Italia.
2. **Bronte V**. "Innate immunity in cancer and Covid-19 patients". Virtual Meeting IRP. 15/12 - 2020.
3. **Bronte V**. "Tumor-driven intrinsic and extrinsic immunosuppression and immune editing". Virtual Meeting. SIC - "Precision Medicine: from tumor biology to clinical trials". 4/12 - 2020.
4. **Bronte V**. "Le frontiere dell'immunologia: circuiti di regolazione/autoimmunità". Virtual Meeting. Leading Immunology - "Il paziente immunologico tra ospedale e territorio: aspetti clinici, assistenziali ed organizzativi". 3/12 - 2020.
5. **Bronte V**. Virtual Meeting. SITC - "35th Anniversary annual meeting". 12/11 - 2020.
6. **Bronte V**. "Innate immune cells in Covid-19 and cancer". XVIII NIBIT Meeting - "COVID-19 at the intersection between cancer, immunity and immunotherapy". 15/10 al 16/10 - 2020.
7. **Bronte V**. Virtual Meeting. "DAB2-expressing TAMs promote cancer cell invasion. Myeloid cells and innate immunity in solid tumors (EK4-2021)". 21/09 al 23/09 - 2020
8. **Bronte V**. 29th Annual short course on experimental models of human cancer - "DAB2-expressing TAMs promote cancer cell invasion". 17/08 al 28/08 - 2020.

9. **Bronte V.** Moderator in “Verona allergy and clinical immunology forum 2020”. 9/01 - 2020. Verona, Italia.
10. **Bronte V.** “The role of tumor-conditioned myeloid cells in shaping anti-tumor immunity”. Esmo Congress. 11/12 al 14/12 - 2019. Ginevra, Svizzera.
11. **Bronte V.** “Immune evasion strategie by myeloid cells in cancer”. 1st International symposium: “Immune evasion in malignant & chronic infectious diseases”. 21/11 al 23/11 - 2019. Deidesheim, Germania.
12. **Bronte V.** “Monocytes and macrophages promote cancer progression by molecular pathways either dependent or independent from adaptive immunity”. 17th ICI, IUIS2019. 19/10 al 23/10 - 2019, Beijing, Cina.
13. **Bronte V.** Chairman in “Macrophages and dendritic cells” session. 17th ICI, IUIS2019. 19/10 al 23/10 - 2019, Beijing, Cina.
14. **Bronte V.** Member of local secretary and chairman in “focus on pancreatic adenocarcinoma and other immune resistant tumors” session. XVII NIBIT Meeting. 11/10 al 13/10 - 2019. Verona, Italia.
15. **Bronte V.** “Myeloid cells in tumors”. Esmo congress. 27/09 al 01/10 - 2019. Barcellona, Spagna.
16. **Bronte V.** “Molecular programs driving pro-tumoral activity in cancer-educated monocytes”. DGfl & SIICA 2019. 10/09 al 10/09 - 2019. Monaco, Germania.
17. **Bronte V.** “Myeloid reprogramming in cancer to divert anti-tumor immune response”. Highlights in immunology and oncohaematology. 18/06 al 19/06 - 2019. Roma, Italia.
18. **Bronte V.** “The role of myeloid-derived suppressor cells in tumor immune evasion”. Summer school immuno-oncology. 10/06 al 12/06 - 2019. Atene, Grecia.
19. **Bronte V.** “Myeloid cells assist tumor progression by molecular mechanisms either dependent or independent from adaptive immunity”. PIVAC-19. 19th International conference on progress in vaccination against cancer. 07/06 al 09/06 - 2019. Atene, Grecia.
20. **Bronte V.** “Modulation of apoptosis and transcriptional activity in tumor-educated, immunosuppressive monocytes”. ICVI: the international symposium on immunotherapy. 24/05 al 25/05 - 2019. Londra. Regno Unito.
21. **Bronte V.** “Monopoiesis in cancer”, 5th workshop on dendritic cell biology. 27/03 al 29/03 - 2019. Lisbona, Portogallo.

22. **Bronte V.** Moderator in "l'Anemia da enteropia: questa sconosciuta". 16/02 - 2019. Verona, Italia.
23. **Bronte V.** "The immune suppressive myeloid environment in cancers", 40th EORTC-PAMM winter meeting. 06/02 al 09/02 - 2019.
24. **Bronte V.** "The cross-talk between cancer and myeloid cells promoter tumor development by immune dependent and independent mechanisms", CIMT academy of translational cancer immunology, winter school. 12/01 al 16/01 - 2019. Obergurgl, Austria.
25. **Bronte V.** "The role of myeloid-derived suppressor cells in tumor immune evasion", 4th symposium on advances in cancer immunology and immunotherapy. 29/11 al 01/12 - 2018. Atene, Grecia.
26. **Bronte V.** "Lesson from cancer: "flipping" over monocytes into immune-suppressive cells", XII annual Ri.MED scientific symposium. 12/10 - 2018. Palermo, Italia.
27. **Bronte V.** "Myelopoiesis in cancer: "flipping" over monocytes into immune regulatory cells", XVI NIBIT meeting. 11/10 al 13/10 - 2018. Milano, Italia.
28. **Bronte V.** "The cross-road between macrophages and dendritic cells: from immunometabolism to single cell fate", chairman of the 32nd annual EMDS (European Macrophage and Dendritic Cell Society). 27/09 al 29/09 - 2018. Milano, Italia.
29. **Bronte V.** "Altered myelopoiesis in cancer", ImmunoRad. 20/09 al 22/09 - 2018. Parigi, Francia.
30. **Bronte V.** "Flipping over monocytes into immune regulatory cells", ECI Congress. 02/09 al 05/09 - 2018. Amsterdam, Paesi Bassi.
31. **Bronte V.** "Macrophages assist metastatic process through the regulation of endocytic pathway", 15th Int'l Conference on innate immunity. 18/06 al 23/06 - 2018. Creta, Grecia.
32. **Bronte V.** "Myelopoiesis and cancer: "flipping" over monocytes into immune suppressive cells", CIMT 2018. 15/05 al 17/05 - 2018. Mainz, Germania.
33. **Bronte V.** "Arginase inhibitors", TAT 2018. 05/03 al 07/03 - 2018. Parigi, Francia.
34. **Bronte V.** "Myelopoiesis and cancer: "flipping" over monocytes into immune suppressive cells + Q&A session", INGM. 13/02 - 2018. Milano, Italia.
35. **Bronte V.** "Alteration of monocyte survival and immune dysfunctions in cancer", Cancer immunotherapy 2017. 28/11 - 2017. Parigi, Francia.

36. **Bronte V.** "Role of myeloid-derived suppressor cells in cancer immune evasion", 23th Congress of EHA. 24/11 - 2017. Amsterdam, Paesi Bassi.
37. **Bronte V.** "Monocytes and macrophage in cancer", SITC 32nd annual meeting. 08/11 al 12/11 - 2017. National Harbor, US.
38. **Bronte V.** "Tumor immunology: from tissue microenvironment to immunotherapy", Ruggero Ceppellini Advanced School of Immunology. 16/10 al 18/10 - 2017. Napoli, Italia.
39. **Bronte V.** "Myeloid regulatory cell biology", final COST AFACTT meeting cell-based tolerance inducing therapies. 11/10 al 13/10 - 2017. Barcellona, Spagna.
40. **Bronte V.** "Myeloid cells assist tumor progression by molecular mechanisms either dependent or independent from adaptive immunity", 17th International conference on progress in vaccination against cancer. 27/09 al 30/09 - 2017. Loutraki, Corinto, Grecia.
41. **Bronte V.** Third annual CRI-CIMT-EATI-AACR international cancer immunotherapy conference. 06/09 al 09/09 - 2017. Mainz, Francoforte, Germania.
42. **Bronte V.** "Immune regulatory programs and poptosis in myeloid-derived suppressor cells", 14th International conference on innate immunity. 19/06 al 24/06 - 2017. Heraklion, Creta.
43. **Bronte V.** "Manipulating the tumor environment", FOCIS - SITC course on cancer immunity and immunotherapy. 14/06 - 2017. Chicago, US.
44. **Bronte V.** "Immuno regulatory pathways in tumor-conditioned monocytes", Istituto italiano di cultura. 24/05 al 26/05 - 2017. Praga, Repubblica Ceca.
45. **Bronte V.** Chairman in "Phagocytes in tumor biology and immunotherapy" session, 51th Annual scientific meeting of the european society for clinical investigation (ESCI conference 2017). 17/05 al 19/05 - 2017. Genova, Italia.
46. **Bronte V.** "Role of myeloid-derived suppressor cells in tumor immunity", Keystone symposia, Cancer immunology and immunotherapy: taking a place in mainstream oncology. 19/03 al 23/03 - 2017. Whistler, Canada.
47. **Bronte V.** "Apoptosis regulation and immune suppressive programs in tumor-conditioned monocytes", 9th Cellular therapy symposium. 16/03 al 17/03 - 2017. Erlangen, Germania.
48. **Bronte V.** "Myeloid-derived suppressor cells and their contribution to tumor immune escape", 2nd Symposium on advances in cancer immunology and

- immunotherapy. 15/12 al 17/12 - 2016. Atene, Grecia.
- 49.**Bronte V.** “Boosting cancer immunotherapy by interfering with myeloid-dependent suppression”, eati.lectures, European Academy of Tumor Immunology. 5/12 - 2016. Parigi, Francia.
- 50.**Bronte V.** “Molecular and metabolic control of adaptive immunity in cancer”, Viruses, Inflammation and Cancer. 14/11 al 16/11 - 2016. Venezia, Italia.
- 51.**Bronte V.** “Altered myelopoiesis and immune dysfunctions during cancer progression”, Easton seminar, Immunology department, University of Toronto. 24/10 - 2016. Toronto, Canada.
- 52.**Bronte V.** “Myeloid derived suppressor cells”, Metchnikoff’s legacy: tissue phagocytes and functions. - EFIS - EJI Ruggero Ceppellini Advanced School of Immunology. 12/10 al 14/10 - 2016. Napoli, Italia.
- 53.**Bronte V.** “Immune suppressive and immune stimulating monocytes in cancer”, second CRI-CIMT-EATI-AACR International cancer immunotherapy meeting. 25/09 al 28/09 - 2016. New York, US.
- 54.**Bronte V.** “Monocyte-dependent regulation of cancer immunotherapy”, 58th Annual Meeting of the Italian Cancer Society. Revolutionary Road: Accelerating Conversion of Cancer Biology into Personalized Clinical Oncology. 5/09 al 8/09 - 2016. Verona, Italia.
- 55.**Bronte V.** “Immune suppressive and immune stimulating monocytes in cancer environment”, Regulatory myeloid suppressor cells conference. 16/06 al 19/06 - 2016. Philadelphia, US.
- 56.**Bronte V.** “Tumor-induced deviation of myeloid cells”, 21st Congress of European Hematology Association. 09/06 al 12/06 - 2016. Copenhagen, Danimarca.
- 57.**Bronte V.** Chairman in “Tumor immunology 2”, session X National Congress of Italian Society of Immunology, Clinical Immunology and Allergology (SIICA). 25/05 al 28/05 - 2016. Abano Terme, Italia.
- 58.**Bronte V.** “ABC di immunologia per oncologi clinici”, Carcinoma renale metastatico: continuità terapeutica e approccio multidisciplinare. 13/05 al 14/05 - 2016. Sirmione, Italia.
- 59.**Bronte V.** “Immune suppressive and immune stimulating monocytes in cancer”, 14th CIMT Annual meeting. 10/05 al 12/05 - 2016. Mainz, Germania.
- 60.**Bronte V.** “Recenti progressi nell’immunoterapia del cancro: la nuova frontiera”, La ricerca che cura: presente e futuro - 25° anniversario delegazione AIRC di

- Gela. 16/04 - 2016. Gela, Italia.
- 61.**Bronte V.** “Immune suppressive mechanisms in cancer microenvironment”, World Immune Regulation meeting - X. 16/03 al 19/03 -2016. Davos, Svizzera.
 - 62.**Bronte V.** “The interplay between L-arginine metabolism and adoptive immunity in cancer”, CIIT seminar. 26/01 - 2016. Innsbruck, Austria.
 - 63.**Bronte V.** “Myeloid stroma and regulation of adaptive immunity in cancer”, Innovative therapy monoclonal antibodies and beyond - 6th Edition. 22/01 - 2016. Milano, Italia.
 - 64.**Bronte V.** “Plenary lecture: modulating the tumor environment to enhance cancer immunotherapy”, San Raffaele Hospital. 16/12 - 2015. Milano, Italia.
 - 65.**Bronte V.** “Myeloid cells regulation of adaptive immunity in cancer”, Second Immunothercan symposium - Inflammation and Immunity in Cancer. 03/12 al 04/12 - 2015. Madrid, Spagna.
 - 66.**Bronte V.** “The interplay between L-arginine metabolism and adoptive immunity in cancer”, 44th Annual meeting of JSI. 18/11 al 20/11 - 2015. Sapporo, Giappone.
 - 67.**Bronte V.** Co-chairman “Innate Immunity”session, SITC 2015. 06/11 al 08/11 - 2015. National Harbor, US.
 - 68.**Bronte V.** “The interplay between L-arginine metabolism and adoptive immunity in cancer”, ICGEB Seminars. 22/10 - 2015. Trieste, Italia.
 - 69.**Bronte V.** “The interplay between L-arginine metabolism and adoptive immunity in cancer”, The Inaugural International Cancer Immunotherapy Conference: translating science into survival. 16/09 al 19/09 - 2015. New York, US.
 - 70.**Bronte V.** “The interplay between L-arginine metabolism and adoptive immunity in cancer”, ECI Congress 2015. 06/09 al 09/09 - 2015. Vienna, Austria.
 - 71.**Bronte V.** “Adoptive cell therapy reprograms tumorinfiltrating myelomonocytic cells”, Cell symposium: Cancer, Inflammation and Immunity. 14/06 al 16/06 - 2015. Sitges, Spagna.
 - 72.**Bronte V.** “Myeloid cells and cancer progression”, AACR Annual meeting 2015. 17/04 al 22/04 - 2015. Philadelphia, US.
 - 73.**Bronte V.** “Interplay between tumor-specific CD8+ T lymphocytes and tumor-infiltrating dendritic cells for successful immunotherapy of cancer”, Istituto Regina Elena. 29/01 - 2015. Roma, Italia.
 - 74.**Bronte V.** “Molecular and metabolic control of antitumor immunity by myeloid

- cells”, Joint DK Retreat in Cell Death, Inflammation and Immunity. 30/11 al 03/12 - 2014. Obergugel, Austria.
- 75.**Bronte V.** “Introduction to innate immunity”, SITC 2014 Annual Meeting. 06/11 al 09/11 - 2014. National Harbor, US.
- 76.**Bronte V.** “Myeloid-derived suppressor cells as targets for cancer immune modulation”, Joint National Ph.D. Meeting 2014. 23/10 al 25/10 - 2014. Pesaro, Italia.
- 77.**Bronte V.** “Molecular and metabolic control of antitumor immunity by myeloid cells”, VII annual Ri.MED symposium. 22/10 - 2014. Milano, Italia.
- 78.**Bronte V.** “Myeloid-derived suppressor cells as targets for cancer immunomodulation”, international symposium on Advanced Oncological Therapies. 14/10 al 16/10 - 2014. Madrid, Spagna.
- 79.**Bronte V.** “Positive and negative myeloid regulators of intra-tumoral adaptive immunity”, 3rd Conference of translational medicine on pathogenesis and therapy of immune-mediated diseases, Workshop Italian Society of Immunology Clinical Immunology and Allergology. 30/09 al 01/10 - 2014. Milano, Italia.
- 80.**Bronte V.** “Myeloid-dependent tolerance: cells and molecular mechanisms”, 3rd International Conference on Immune Tolerance 2014, NH Grand Kransapolsky. 28/09 al 30/09 - 2014. Amsterdam, Paesi Bassi.
- 81.**Bronte V.** Chairman at PIVAC, 14th International Conference on Progress in Vaccination Against Cancer. 24/09 al 26/09 - 2014. Roma, Italia.
- 82.**Bronte V.** “Regulation of intratumoral L-arginine metabolism by adaptive immunity”, Max Delbrück Center for Molecular Medicine. 07/07 al 09/07 - 2014. Berlino, Germania.
- 83.**Bronte V.** “Molecular and metabolic control of adaptive immunity in cancer”, King’s College. 01/07 al 03/07 - 2014. Londra, UK.
- 84.**Bronte V.** “Molecular and metabolic control of antitumor immunity by myeloid cells”, the German Cancer Research Center (DKFZ). 02/06 al 04/06 - 2014. Heidelberg, Germania.
- 85.**Bronte V.** “Myeloid-derived suppressor cells in cancer”, IX National Conference of the Italian Society of Immunology and Allergology (SIICA). 28/05 al 31/05 - 2014. Firenze, Italia.
- 86.**Bronte V.** “Regulation of intra-tumoral L-arginine metabolism by adaptive immune response”, Translational immunology 2014. 11/04 al 12/04 - 2014.

Würzburg, Germania.

- 87.**Bronte V.** “Tumor-induced immune suppression by MDSC”, Keystone symposium 2014. 09/03 al 15/03 - 2014. Vancouver, Canada.
- 88.**Bronte V.** “Myeloid-derived suppressor cells: molecular characterization and therapeutic targeting”, Seminar in Onco Immunology. 05/02 al 06/02 - 2014. Toulouse, Francia.
- 89.**Bronte V.** “Role of macrophage in adaptive and innate immunity, models and tools to study macrophage functions”, EASL Basic School of Hepatology. 24/01 al 25/01 - 2014. Milano, Italia.
- 90.**Bronte V.** “Molecular and metabolic control of adaptive immunity in cancer”, Seminar at Brunel University. 16/12 al 18/12 - 2013. London, UK.
- 91.**Bronte V.** “Molecular and metabolic control of adaptive immunity in cancer”, Distinguished Lecture Series - The Wistar Institute. 26/11 al 27/11 - 2013. Philadelphia, US.
- 92.**Bronte V.** “Molecular and metabolic control of adaptive immunity in cancer”, University Loyola. 24/11 al 26/11 - 2013. Chicago, US.
- 93.**Bronte V.** “Introduction to innate immunity”, Society for Immunotherapy. 28/10 al 01/11 - 2013. Suzhou, Cina.
- 94.**Bronte V.** “Cancer metabolism and immune suppression”, 11th NIBIT Meeting, Cancer Bio-Immunotherapy. 17/10 al 19/10 - 2013. Siena, Italia.
- 95.**Bronte V.** “Control of tumor-induced immunoregulatory network by microRNAs”, Gene Vaccination in Cancer. 09/10 al 11/10 - 2013. Ascoli Piceno, Italia.
- 96.**Bronte V.** “Modulation of tumor microenvironment by microRNAs”, 13th International Conference on Progress in Vaccination Against Cancer, PIVAC-13. 02/10 al 04/10 - 2013. Amsterdam, Paesi Bassi.
- 97.**Bronte V.** “Molecular regulation of myeloid-dependent immune suppression”, Danish Cancer Society symposium. 23/09 al 25/09 - 2013. Copenhagen, Danimarca.
- 98.**Bronte V.** “Molecular and metabolic control of adaptive immunity by tumor-induced myelopoiesis”, DGf1 Annual Meeting German Society for Immunology. 12/09 al 14/09 - 2013. Mainz, Germania.
- 99.**Bronte V.** “Molecular regulation of innate immunity in tumor microenvironment”, ICI 2013, 15th International Congress of Immunology. 22/08 al 27/08 - 2013. Milano, Italia.

100. **Bronte V.** "Tissue Remodeling: learning from tumor microenvironment", CTS Cell Transplant Society. 07/07 al 11/07 - 2013. Milano, Italia.
101. **Bronte V.** "Control of tumor-induced immunoregulatory network by microRNAs", Roche Nature Medicine Immunology symposium. 28/04 al 30/04 - 2013. Buonas, Svizzera.
102. **Bronte V.** "Myeloid-derived suppressor cells", Keystone symposia, Cancer Immunology and Immunotherapy (J4). 27/01 al 01/02 - 2013. Vancouver, Canada.
103. **Bronte V.** "A tolerogenic environment in the spleen of tumor-bearing hosts", Lund Immunology Seminars Series, Lund University. 20/01 al 21/01 - 2013. Lund, Svezia.
104. **Bronte V.** "Chemotherapy alters a tolerogenic environment in the spleen of tumor bearing hosts", SITC Workshop Faculty, Society for Immunotherapy of Cancer. 24/10 al 25/10 - 2012. North Bethesda. US.
105. **Bronte V.** "A tolerogenic environment in the spleen of tumor-bearing hosts", Cancer Research Institute - From Milestones to Medicines: Translating Tumor Immunology Research into Immunotherapies. 01/10 - 03/10 - 2012. New York, US.
106. **Bronte V.** "CCL2 orchestrates a tolerogenic environment in the spleen of tumor-bearing hosts", Joint Annual Meeting of the International Cytokine Society (ICS) and the International Society for Interferon and Citokine Research (ISICR). 11/09 al 14/09 - 2012. Ginevra, Svizzera.
107. **Bronte V.** "A tolerogenic environment in the spleen of tumor-bearing hosts". European Congress of Immunology. 01/09 - 05/09 - 2012. Glasgow, Scozia.
108. **Bronte V.** "CCL2 orchestrates a tolerogenic environment in the spleen of tumor-bearing hosts", EMDS European Macrophages and Dendritic Cell Society. 01/09 al 03/09 - 2012. Debrecen, Ungheria.
109. **Bronte V.** "Cancer-induced peripheral tolerance occurs in a specialized splenic niche", Center for Cancer Immunology Research Grand Rounds Seminar Series. 13/06 al 15/06 - 2012. Houston, US.
110. **Bronte V.** "Interfering with tumor-induced myelopoiesis to enhance adoptive immunotherapy of cancer", Immunity and Inflammation in Disease", 7th International HBGP Student Council Symposium. 07/06 al 08/06 - 2012. Helsinki, Finlandia.

111. **Bronte V.** "The cancer macroenvironment modulates adaptive immunity against cancer". Immunology and Medicine Seminars. 31/05 al 02/06 - 2012. Cambridge, UK.
112. **Bronte V.** "Applicazioni in oncologia e immunologia", corso avanzato in citometria a flusso. 22/05 al 23/05 - 2012. Verona, Italia.
113. **Bronte V.** "L'allergologia e immunologia nel terzo millennio: from bedside to bench, dalla clinica alla proteomica", 111° Congresso Nazionale della Federazione delle Società Italiane di Immunologia, Allergologia e Immunologia Clinica (IFIACI). 02/05 al 05/05 - 2012. Verona, Italia.
114. **Bronte V.** "Cancer microenvironment and immune evasion. International symposium changing the microenvironment: new strategies for immunotherapy". 21/03 al 22/03 - 2012. Pamplona, Spagna.
115. **Bronte V.** "Cancer and immunosuppression" 2nd EFIS-EJI Intensive Educational Course in Clinical Immunology. 28/11 al 30/11 - 2011. Parigi, Francia.
116. **Bronte V.** "Post-translational chemokine modification prevents intratumoral infiltration of antigen-specific T cells", NCRI Cancer Conference. 06/11 al 09/11 - 2011. Liverpool, UK.
117. **Bronte V.** "Post-translational chemokine modification prevents intratumoral infiltration of antigen-specific T cells", SITC Cancer Conference. 04/11 al 06/11 - 2011. North Bethesda, US.
118. **Bronte V.** "Interfering with the mechanisms of myeloid-dependent immune suppression in cancer: evidence in mice and humans". ESCII/NIBIT Meeting 2011, New perspectives in the immunotherapy of cancer. 19/10 al 22/10 - 2011. Siena, Italia.
119. **Bronte V.** "Pancreatic carcinoma and immunity, escape from immune system: from bench to bedside", XXV Congresso AISP. 13/10 al 15/10 - 2011. Peschiera del Garda, Italia.
120. **Bronte V.** "Post-translational chemokine modification prevents intratumoral infiltration of antigen-specific T cells", Progress in vaccination against cancer - PIVAC 2011. 10/10 al 13/10 - 2011. Copenhagen, Danimarca.
121. **Bronte V.** "Interfering with myeloid-dependent suppression to enhance the efficacy of cancer immunotherapy", SIICA. 28/09 al 01/10 - 2011. Riccione, Italia.
122. **Bronte V.** "Post-translational chemokine modification in cancer: a strategy to control myeloid and lymphoid cell recruitment", International meeting

- Chemokines and Chemokine receptors in cancer: role of microenvironment. 26/09 al 27/09 - 2011. Napoli, Italia.
- 123.**Bronte V.** "Targeting myeloid-dependent suppression to improve cancer immunotherapy", 5th Aspen Symposium on Brain Tumor ImmunoTherapy. 31/07 al 03/08 - 2011. Limelight Lodge Aspen, US.
- 124.**Bronte V.** "Tumor immune evasion based on altered myelopoiesis: cells and molecular mechanisms", 5th Aspen Symposium on Brain Tumor ImmunoTherapy. 31/07 al 03/08 - 2011. Limelight Lodge Aspen, US.
- 125.**Bronte V.** "Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells", 4th Waddensymposium on Novel strategies in immunotherapy of cancer. 26/06 al 29/06 - 2011. Texel, Paesi Bassi.
- 126.**Bronte V.** "Myeloid-derived suppressor cells in cancer. Annual European Congress of Rheumatology "EULAR 2011". 25/05 al 28/05 - 2011. Londra, UK.
- 127.**Bronte V.** "Immunologia dei tumori: myeloid-suppressor cells", Accademia Medica di Roma. 24/03 - 2011. Roma, Italia.
- 128.**Bronte V.** "Interfering with myeloid-dependent suppression to enhance the efficacy adoptive cell therapy of cancer", an International Immunopharmacology Conference - Regulatory Myeloid Cells. 21/10 al 24/10 - 2010. Arlington, US.
- 129.**Bronte V.** "Tumor-induced tolerance and immune suppression depend on C/EBP β transcription factor", International Viruses, Genes and Cancer Conference. 29/09 al 01/10 - 2010. Venezia, Italia.
- 130.**Bronte V.** "Interfering with myeloid-dependent suppression to enhance the efficacy of adoptive cell therapy of cancer", DC2010: forum on vaccine science. 26/09 al 30/09 - 2010. Venezia, Italia.
- 131.**Bronte V.** "Interfering with myeloid-dependent suppression to enhance the efficacy of adoptive cell therapy of cancer", Annual Meeting DGfl German Society for Immunology. 22/09 al 25/09 - 2010. Liepzing, Germania.
- 132.**Bronte V.** "Controlling myeloid-derived suppressor cells to enhance cancer immunotherapy", 4^{eme} Journées scientifiques Miltenyi Biotec. From inflammation to immunomodulation in cancer. Cordeliers Institute. 24/06 - 2010. Parigi, Francia.
- 133.**Bronte V.** "Cross-talk between cancer and bone marrow for the generation of myeloid-derived suppressor cells: the concept of cancer macroenvironment", 101st AACR Annual meeting. 07/04 al 21/04 - 2010. Washington, US.

- 134.**Bronte V.** “Myeloid-derived suppressor cells: moving from mouse to human”, European Society for Clinical Investigation, 44th annual scientific meeting. 24/02 al 27/02 - 2010. Bari, Italia.
- 135.**Bronte V.** “Myeloid-derived suppressor cells”, Keystone symposium on: The Macrophage - Intersection of Pathogenic and Protective Inflammation. 12/02 al 17/02 - 2010. Banff, Canada.
- 136.**Bronte V.** “Forced myelopoiesis and immune deviation in cancer”, Keystone symposium on: Molecular and Cellular Biology of Immune Escape in Cancer. 07/02 al 12/02 - 2010. Keystone, US.
- 137.**Bronte V.** “Immunotherapy and immunopathology with either telomerase-specific vaccines or telomerase-specific CTLs”, Cancer Vaccine-Adjuvants-Delivery for the next decade (CVAAD) meeting. 11/11 al 13/11 - 2009. Dublino, Irlanda.
- 138.**Bronte V.** “Learning tolerance from cancer: lessons from myeloid-derived suppressor cells”, Tri-Society meeting of ICI, ISICR and SLB. 18/10 al 21/10 - 2009. Lisbona, Portogallo.
- 139.**Bronte V.** “Interazioni tra tumori e midollo osseo nell’induzione di cellule soppressorie di derivazione mieloide. Microambiente tumorale: ruolo nella progressione neoplastica e nell’immunoregolazione”. 14/10 - 2009. Genova, Italia.
- 140.**Bronte V.** “Myeloid-derived suppressor cells”, EACR Special Conference: inflammation and cancer. 24/09 al 25/09 - 2009. Berlino, Germania.
- 141.**Bronte V.** “Myeloid-derived suppressor cells”, The 2nd European Congress of Immunology. 13/09 al 16/09 - 2009. Berlino, Germania.
- 142.**Bronte V.** “Monocyte and macrophage heterogeneity”, Translational Research in Pediatric Rheumatology (TRiPR), second conference. Innate Immunity and the Pathogenesis of Rheumatic Diseases. 06/05 al 08/05 - 2009. Genova, Italia.
- 143.**Bronte V.** “Mechanisms of MDSC mediated immuno suppression”, Molecular targets for cancer therapy: fifth biennial meeting. 12/03 al 15/03 - 2009. Clearwater Beach, US.
- 144.**Bronte V.** “Origin and function of myeloid-derived suppressor cells monocytes, macrophage and dendritic cell heterogeneity”. 02/03 al 07/03 - 2009. Treilles, Francia.

145. **Bronte V.** "Myeloid-derived suppressor cells as negative regulators of the immune response: from cancer to transplantation", Pasteur Institute. 19/12 - 2008. Parigi, Francia.
146. **Bronte V.** "Learning tolerance from cancer: the lesson of myeloid-dependent suppression. Tumor Immunology: New Perspectives", AACR Special Conference in Cancer Research. 02/12 al 05/12 - 2008. Miami, US.
147. **Bronte V.** "Tumor-induced barriers to immune assault", IRB Conference room. 30/10 - 2008. Bellinzona, Svizzera.
148. **Bronte V.** "Myeloid suppressor cells and immune escape. Tumor immune escape 2008.", Ruggero Ceppellini School of Immunology. 16/10 al 18/10 - 2008. Sorrento, Italia.
149. **Bronte V.** "Immunosuppressive networks in cancer. Altered myeloid differentiation and immune dysfunctions in cancer. From tumor immunology to immune therapy of cancer - course No.1594", Karolinska Institute. 19/09 - 2008. Stoccolma, Svezia.
150. **Bronte V.** "Myeloid-derived suppressor cells in cancer. Cancer immunology & immunotherapy 2008: from discovery to development to drug", 16th Annual International Cancer Immunotherapy Symposium. 15/09 al 17/09 - 2008. New York, US.
151. **Bronte V.** "Myeloid suppressor cells in the regulation of immune responses". Innate immunity and inflammation in transplantation. 26/06 al 27/06 - 2008. Nantes, Francia.
152. **Bronte V.** "Myeloid-derived suppressor cells in cancer". The Giovanni Armenise-Harvard Fondation. 12th Annual Symposium - Cancer: from genes and proteins to pathway and therapeutics. 20/06 al 23/06 - 2008. Stresa, Italia.
153. **Bronte V.** "Cancer-induced barrier to immune response: role of myeloid-derived suppressor cells". Tumor immunology meets oncology 4th. 23/05 al 24/05 - 2008. Halle, Germania.
154. **Bronte V.** "Myeloid-derived suppressor cells in cancer". British Inflammation Research Association Symposium Inflammation and Cancer. 23/05 - 2008. Londra, UK.
155. **Bronte V.** "Dissecting the complexity of myeloid-derived suppressor cells". The tolerogenic nature of tumor-associated inflammation: relevance for LCH? 18th Nikolas Symposium. 02/05 al 05/05 - 2008. Corint, Greece.

- 156.**Bronte V.** “Cancer induced barrier against immune system: myeloid-derived suppressor cells”. Immunology of health and disease conference. 09/03 al 14/03 - 2008. Cape Town, Sud Africa.
- 157.**Bronte V.** “Metabolic restraint of T lymphocyte activation and migration by tumor-conditioned myeloid cells. Integrative cancer genomics”. 11/02 al 13/02 - 2008. Monaco, Germania.
- 158.**Bronte V.** “Myeloid-derive suppressor cells in cancer”. Centro Nacional de Biotecnología/CSIC. 18/01 - 2008. Madrid, Spagna.
- 159.**Bronte V.** “System biology of tumor-associated macrophages”. MicroRNA in Biology and Disease. 04/12 - 2007. Milano, Italia.
- 160.**Bronte V.** “The biology and function of myeloid-derived suppressor cells”. Inflammation and Cancer. 08/11 al 09/11 - 2007. Milano, Italia.
- 161.**Bronte V.** “Myeloid-derive suppressor cells in cancer”. International Society for the Biological Therapy of Cancer, 22nd Annual meeting. 02/11 al 04/11 - 2007. Boston, US.
- 162.**Bronte V.** “Altered macrophage differentiation and T lymphocyte dysfunctions during tumor development”. 40th Annual meeting of the Society of Leukocyte Biology. 11/10 al 13/10 - 2007. Cambridge, US.
- 163.**Bronte V.** “Altered macrophage differentiation and immune dysfunction in tumor development”. Cancer and inflammation, annual symposium of the NCI Center of Excellence in Immunology. 09/10 al 10/10 - 2007. Bethesda, US.
- 164.**Bronte V.** “Immune response regulation by tumor conditioned myeloid-derived suppressor cells. Regulatory pathways in autoimmunity and cancer”. BSI Golden Jubilee Year - BSI Wessex Regional Group. 02/10 - 2007. Southampton, UK.
- 165.**Bronte V.** “Altered myeloid differentiation and immune dysfunctions in cancer”, Seventh International Conference on Progress in Vaccination Against Cancer (PIVAC). 09/09 al 11/09 - 2007. Stoccolma, Svezia.
- 166.**Bronte V.** “The dual personality of myeloid-derived suppressor cells”. International Seminar Series. Department of Neurosurgery, University Hospital. 19/04 - 2007. Svezia.
- 167.**Bronte V.** “Myeloid-derived suppressor cells in cancer: a novel target for therapeutic invention. Cancer Immunotherapy meets strategies for immunotherapy”. 5th Annual meeting. 12/04 al 14/04 - 2007. Würzburg, Germania.

168. **Bronte V.** "Special lecture: myeloid suppressor cells in cancer". Keystone symposium. The potent new anti-tumor immunotherapies. 28/03 al 02/04 - 2007. Fairmont Banff Springs, Canada.
169. **Bronte V.** "The dual personality of myeloid-derived suppressor cells. Novel mechanisms of immune tolerance in tumor immunology and stem cell/organ transplantation". 21/02 - 2007. Bologna, Italia.
170. **Bronte V.** "Inflammatory monocytes induced by tumors alter T-lymphocyte responsiveness through L-arginine metabolism". 4th biennial molecular targets in cancer therapy: mechanism & therapeutic reversal of immune suppression in cancer. 25/01 al 28/01 - 2007. Sheraton Sand Key Resort, Clearwater Beach, US.
171. **Bronte V.** "Correction of altered arginine metabolism to boost antitumor immune response". Italian Melanoma Intergroup 12th annual meeting. 30/11 al 02/12 - 2006. Bari, Italia.
172. **Bronte V.** "Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. IT-2006: targeting complexity". 15/11 al 19/11- 2006. La Habana, Cuba.
173. **Bronte V.** "Cellule mieloidi soppressorie e tumori. Corso di aggiornamento: "meccanismi di immunosoppressione e immunoterapia dei tumori", IST. 07/11 - 2006. Genova, Italia.
174. **Bronte V.** "Development of novel approaches to overcome to overcome immunological dysfunctions in preclinical tumors models". Development and functions of immune system: new insights from study of mouse models. Università degli Studi di Roma "La Sapienza". 31/10 - 2006. Roma, Italia.
175. **Bronte V.** "Regulation of immune responses by L-arginine metabolism", 6th Beaune seminar in transplant research. 19/10 al 20/10 - 2006. Beaune, Francia.
176. **Bronte V.** "Arginine metabolism in myelomonocytic cells affects T lymphocyte response to antigen", 20th Annual meeting of the European Macrophage and Dendritic Cell Society (EMDS). Immunoregulatory and Antimicrobial Activities of Myeloid Cells. 05/10 al 07/10 - 2006. Freiburg, Germania.
177. **Bronte V.** "Altered L-arginine metabolism in cancers restrains anti-tumor T lymphocyte response". 16th European Congres of Immunology. 06/09 al 09/09 - 2006. Parigi, Francia.

- 178.**Bronte V.** “Genetic vaccines for the active immunotherapy of cancer”. Biological therapy of cancer. 21/06 al 24/06 - 2006. Dresden, Germania.
- 179.**Bronte V.** “Mouse myeloid suppressor cells comprise a peculiar population of inflammatory monocytes”. Istituto Superiore di Sanità, immunotherapy of Cancer: challenges and needs. 24/05 al 25/05 - 2006. Roma, Italia,
- 180.**Bronte V.** “L-arginine metabolism and immune dysfunction in cancer”. CIMT 2006 meets strategies for immune therapy. 04/05 al 05/05 - 2006. Mainz, Germania.
- 181.**Bronte V.** “L-arginine metabolism in tumor-bearing hosts affects T lymphocyte responsiveness. SIC-SIICA: tumor immunology”. 47° Congresso Nazionale della Società Italiana di Cancerologia. 02/10 al 05/10 - 2005. Abano Terme, Italia.
- 182.**Bronte V.** “Myeloid suppressor cells control T lymphocyte activation during physiological and pathological immune responses”. XV Congresso AINI - Associazione Italiana Neuroimmunologia, 13/10 al 15/10 - 2005. Abbazia di Praglia, Teolo, Italia.
- 183.**Bronte V.** “A critical assessment of the progress of cancer vaccines”. Cancer vaccines/adjuvants/delivery for the next decade (CVADD 2005). 05/09 al 07/09 - 2005. Lisbona, Portogallo.
- 184.**Bronte V.** “Checkpoint manipulation in tumor immunotherapy”. ESO advanced course, immunology for oncologists. 16/04 al 18/04 - 2005. Ascona, Svizzera.
- 185.**Bronte V.** “L-arginine metabolism in CD11+/Gr-1+ myeloid suppressor cells inhibits T lymphocyte function”. 15/11 al 19/11 - 2004. La Habana, Cuba.
- 186.**Bronte V.** “Animal models”. Trends in prostate cancer 2004. What is new? 24/09 - 2004. Padova. Italia.
- 187.**Bronte V.** “L-arginine catabolism in myeloid suppressor cells as a toll to restrain T cell response”. Immune Evasion. 25/03 al 30/03 - 2004. New Mexico, US.
- 188.**Bronte V.** “L-arginine metabolism in CD11+/Gr-1+ myeloid cells restrains T lymphocyte functions”. Basic Aspects of Vaccines Meeting. 28/04 al 30/04 - 2004. Bethesda, US.
- 189.**Bronte V.** Serafini P, De Santo C, Marigo I, Tosello V, Mazzoni A, Segal DM, Colombo MP, Zanovello P. “Immune dysfunctions induced by myeloid suppressor cells in tumor-bearing mice. Keystone symposium on basic aspects of tumor immunology”. 17/02 al 24/02 - 2003. Keystone, US.

190. **Bronte V.** "Cytokines and molecularly defined adjuvants can either enhance or restrain the efficacy of recombinant cancer vaccines. Cytokines as natural adjuvants: perspectives for vaccine development". Istituto Superiore di Sanità. 22/04 al 24/04 - 2002. Roma, Italia.

BREVETTI

1. Serafini P, Biccato S, Caroly J, De la Fuente A, Van Simaey D, Zilio S, **Bronte V.** (2019). ***RNA aptamers and uses thereof.*** University of Miami, Florida, US. PCT/US2020/020799
2. Serafini P, **Bronte V.** (2017). ***Nanoparticle conjugates and uses thereof.*** University of Miami, Florida, US. PCT/EP2017/1453.
3. **Bronte V,** Ugel S, Fiore A, Sahin U. (2017). ***Engineered cells for inducing tolerance.*** BioNTECH AG. 674-208 PCT.
4. Ugel S, Sandri S, Bobisse S, **Bronte V.** (2015). ***Gene sequence encoding a mouse TCR specific for the human HLA-A2 complex and hTERT865-873 peptide and its use for engineering human T lymphocytes for adoptive cell therapy of cancer.*** Università di Verona. PCT/IB2016/051510.
5. **Bronte V,** Viola A, Gasco A, Fruttero R, Crosetti M. (2011). ***Water soluble furoxan derivatives having antitumor activity.*** Humanitas Mirasole Spa, Istituto Oncologico Veneto IRCCS. PCT/IB2011/050743.
6. Singh H, Mendrzyk R, Walter S, **Bronte V,** Mandruzzato S. (2010). ***Use of myeloid cell biomarkers for diagnosis of cancer.*** Immatics Biotechnologies GmbH. 2912919-026000.
7. **Bronte V,** Mandruzzato S. (2009). ***Myeloid-derived suppressor cells generated in vitro.*** Istituto Oncologico Veneto IRCCS. PCT/IB2009700137.
8. **Bronte V,** Viola A, Gasco A, Fruttero R, Crosetti M. (2009). ***Nitric oxide furoxan derivative compounds endowed with antitumoral activity.*** Humanitas Mirasole Spa, Istituto Oncologico Veneto IRCCS. PCT/EP2009/000206.
9. Borrello IM, Serafini P, Noonan KA, **Bronte V.** (2006). ***PDE5 Inhibitor compositions and methods for immunotherapy.*** The Johns Hopkins University. PCT/US06/00699.

SOCIETÀ SCIENTIFICHE

- Membro dell’American Association for Cancer Research (AACR).
- Membro dell’American Association for Immunologists (AAI).
- Membro della Società Italiana di Immunologia, Immunologia Clinica ed Allergologia (SIICA).
- Membro del Network Italiano per la BioTerapia dei Tumori (NIBIT).
- Membro dell’Associazione Nazionale di Medicina (ANM).
- Membro della Società Italiana di Cancerologia (SIC).

REVISORE (REFEREE)

“Ad hoc reviewer” per: Science, Nature Medicine, Nature Immunology, Nature Genetics, Nature Reviews Immunology, Immunity, Cancer Cell, Nature Communications, Journal of Experimental Medicine, Journal of Clinical Investigation, Cancer Discovery, Journal of Immunology, Gastroenterology, Cell Reports, Blood, Proceedings of the National Academy of Science, American Journal of Pathology, Cancer Research, Cancer Immunology Research, Journal of Immunotherapy, European Journal of Immunology, International Journal of Cancer, Journal of Translational Medicine, Human Gene Therapy, Vaccine, Cellular Immunology, Immunology Letters, Clinical Immunology, Cancer Letters, Cancer Immunology Immunotherapy, Journal of Leukocyte Biology, FEBS Letters, Oncoimmunology, Oncotargets.

MEMBRO DI COMMISSIONI

- Peer Reviewer per European Research Council (ERC) Grant Applications.
- Peer Reviewer per National Institutes of Health (NIH) Grant Applications US.
- Peer Reviewer per Evaluation Process of Laboratories of Excellence ANR (French Research Funding Agency).
- AIRC Fellowship Reviewer, Member of Advisor Scientific Board, Italia.
- Peer Reviewer per National Medical Research Council (NMRC) Grant Applications, Singapore.

- Peer Reviewer per Danish Council for Independent Research, Ministry of Higher Education and Science, Danimarca.
- Peer Reviewer per Stichting Tegen Kanker - Fondation contre le Cancer Grant, Belgio.
- Comitato di visita di controllo dell'attività di ricerca dell'unità "Tumor Immunology and Immunotherapy of Cancer", Institut Gustave Roussy, Aeres, Francia.
- Peer Reviewer per Cancer Research UK Grant Applications, UK.
- Peer Reviewer per "SIR 2014" del MIUR Italia.
- Membro del "SITC Fellowship Task Force".
- Expert Reviewer per il "MATWIN PROGRAMME".
- Membro del Review Committee Breast Cancer Now's Research Unit al King College, Londra, 8 Febbraio 2018.
- Peer Reviewer per Independent Research Fund Denmark - Medical Science Grant Applications.
- Peer Reviewer per Swedish Research Council Grant Applications.
- Peer Reviewer per Université Bourgogne Franche-Comté Grant Applications (UBFC).
- Panel Chair in the Evaluation of Proposals submitted to the 2021 ERC Consolidator Grant call.

COLLABORAZIONI CON DITTE FARMACEUTICHE

- IO Biotech ApS
- BioNTech AG
- Ganymed Pharmaceuticals AG
- Xios Therapeutics
- Incyte Corporation
- Emd Serono
- Calithera Bioscience Inc.
- Roche Ltd
- ITeos Therapeutics SA
- Tusk Therapeutics Ltd
- Moderna Inc.

